<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ABSORICA- isotretinoinÂ capsuleÂ </strong><br>Ranbaxy Laboratories Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ABSORICA safely and effectively. See full prescribing information for ABSORICA.<br>ABSORICA<span class="Sup">Â®</span> (isotretinoin) capsules, for oral use<br>Initial U.S. Approval: 1982 <br>
</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: CAUSES <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">BIRTH DEFECTS</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<p class="Highlighta"><span class="Bold">Pregnancy Category X.</span> </p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">ABSORICA must not be used by female patients who are or may become pregnant (<a href="#s16">5</a>, <a href="#s74">8.1</a>, <a href="#s81">8.6</a>).</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">There is an extremely high risk that severe <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> will result if pregnancy occurs while taking ABSORICA in any amount, even for short periods of time. Potentially any fetus exposed during pregnancy can be affected (<a href="#s17">5.1</a>, <a href="#s74">8.1</a>).</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">There are no accurate means of determining whether an exposed fetus has been affected (<a href="#s17">5.1</a>, <a href="#s74">8.1</a>).</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">ABSORICA is available only through a restricted program called the iPLEDGE program. Prescribers, patients, pharmacies, and distributors must enroll in the program (<a href="#s20">5.2</a>).</span></dd>
</dl>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: CAUSES <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">BIRTH DEFECTS</span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<p class="Highlighta"><span class="Bold">Pregnancy Category X.</span> </p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">ABSORICA must not be used by female patients who are or may become pregnant (<a href="#s16">5</a>, <a href="#s74">8.1</a>, <a href="#s81">8.6</a>).</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">There is an extremely high risk that severe <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> will result if pregnancy occurs while taking ABSORICA in any amount, even for short periods of time. Potentially any fetus exposed during pregnancy can be affected (<a href="#s17">5.1</a>, <a href="#s74">8.1</a>).</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">There are no accurate means of determining whether an exposed fetus has been affected (<a href="#s17">5.1</a>, <a href="#s74">8.1</a>).</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">ABSORICA is available only through a restricted program called the iPLEDGE program. Prescribers, patients, pharmacies, and distributors must enroll in the program (<a href="#s20">5.2</a>).</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ABSORICA is a retinoid indicated for the treatment of severe recalcitrant nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> in patients 12 years of age and older (<a href="#s2">1</a>). </p>
<p class="Highlighta"><span class="Underline">Limitations of Use</span> </p>
<p class="Highlighta">ABSORICA may only be administered to patients enrolled in the iPLEDGE program (<a href="#s2">1</a>, <a href="#s20">5.2</a>). </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Recommended dosage of 0.5 to 1 mg/kg/day given in two divided doses without regards to meals for 15 to 20 weeks (<a href="#s5">2.1</a>).</dd>
<dt>â€¢</dt>
<dd>Once daily dosing is <span class="Bold">not</span> recommended (<a href="#s5">2.1</a>).</dd>
<dt>â€¢</dt>
<dd>Perform pregnancy tests prior to prescribing, each month during therapy, end of therapy, and one month after discontinuation (<a href="#s8">2.4</a>, <a href="#s81">8.6</a>).</dd>
<dt>â€¢</dt>
<dd>Prior to prescribing, perform fasting lipid profile and liver function tests (<a href="#s8">2.4</a>).</dd>
<dt>â€¢</dt>
<dd>ABSORICA is not substitutable with other forms of isotretinoin (<a href="#s89">12.3</a>).</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Capsules: 10 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg ( <a href="#s12">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Pregnancy (<a href="#s14">4.1</a>, <a href="#s74">8.1</a>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to this product or any of its components (<a href="#s15">4.2</a>, <a href="#s40">5.14</a>)</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Unacceptable Contraception: Micro-dosed progesterone preparations are not an acceptable method of contraception during ABSORICA therapy (<a href="#s21">5.3</a>)</dd>
<dt>â€¢</dt>
<dd>Psychiatric Disorders: <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, suicidal thoughts and behavior, and aggressive and/or <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">violent behaviors</span> (<a href="#s23">5.4</a>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">Pseudotumor cerebri</span>, some cases with concomitant tetracyclines (<a href="#s24">5.5</a>)</dd>
<dt>â€¢</dt>
<dd>Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>: <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> (SJS), <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN) (<a href="#s25">5.6</a>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">Acute pancreatitis</span>, rarely fatal <span class="product-label-link" type="condition" conceptid="4185268" conceptname="Acute hemorrhagic pancreatitis">hemorrhagic pancreatitis</span>, in patients with either elevated or normal serum triglyceride levels (<a href="#s26">5.7</a>)</dd>
<dt>â€¢</dt>
<dd>Lipid Abnormalities: Triglyceridemia low HDL and elevation of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. Monitor lipid levels at regular intervals (<a href="#s27">5.8</a>, <a href="#s41">5.15</a>)</dd>
<dt>â€¢</dt>
<dd>Hearing Impairment (<a href="#s28">5.9</a>)</dd>
<dt>â€¢</dt>
<dd>Hepatotoxicity: Monitor liver function tests at regular intervals (<a href="#s29">5.10</a>, <a href="#s41">5.15</a>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">Inflammatory Bowel Disease</span> (<a href="#s30">5.11</a>)</dd>
<dt>â€¢</dt>
<dd>Skeletal Abnormalities: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgias</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, decreases in bone mineral density and <span class="product-label-link" type="condition" conceptid="4232188" conceptname="Premature epiphyseal closure">premature epiphyseal closure</span> (<a href="#s31">5.12</a>)</dd>
<dt>â€¢</dt>
<dd>Ocular Abnormalities: corneal opacities, <span class="product-label-link" type="condition" conceptid="374037" conceptname="Night blindness">decreased night vision</span> (<a href="#s36">5.13</a>)</dd>
<dt>â€¢</dt>
<dd>Glucose and CPK Abnormalities (<a href="#s41">5.15</a>)</dd>
</dl></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (incidence â‰¥5%) are: <span class="product-label-link" type="condition" conceptid="4039954" conceptname="Cheilosis">lip dry</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4039954" conceptname="Cheilosis">chapped lips</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, blood creatine kinase increased, <span class="product-label-link" type="condition" conceptid="4301764" conceptname="Cheilitis">cheilitis</span>, musculoskeletal <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="376402" conceptname="Low vision, one eye">visual acuity reduced</span> (<a href="#s47">6.1</a>). </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Ranbaxy, Inc. at 1-800-406-7984 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch or iPLEDGE at (1-866-495-0654).</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Vitamin A: may cause additive adverse reactions (<a href="#s67">7.1</a>)</dd>
<dt>â€¢</dt>
<dd>Tetracyclines: avoid concomitant use (<a href="#s68">7.2</a>)</dd>
<dt>â€¢</dt>
<dd>St. John's Wort: may interfere with oral contraceptives (<a href="#s70">7.4</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 8/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: CAUSES <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">BIRTH DEFECTS</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dosage</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosage Range</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Duration of Use</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Laboratory Testing</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Pregnancy</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Embryofetal Toxicity</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 iPLEDGE Program</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Unacceptable Contraception</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Psychiatric Disorders</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">Pseudotumor Cerebri</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Lipid Abnormalities</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Hearing Impairment</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Hepatotoxicity</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">Inflammatory Bowel Disease</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Skeletal Abnormalities</a></h2>
<h2><a href="#section-5.13" class="toc">5.13 Ocular Abnormalities</a></h2>
<h2><a href="#section-5.14" class="toc">5.14 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-5.15" class="toc">5.15 Laboratory Monitoring for Adverse Reactions</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Vitamin A</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Tetracyclines</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Phenytoin</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 St. John's Wort</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Systemic Corticosteroids</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Norethindrone/ethinyl estradiol</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Females of Childbearing Potential</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis and Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>WARNING: CAUSES <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">BIRTH DEFECTS</span></h1>
<p class="First"><span class="Bold">Pregnancy Category X.</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">ABSORICA must not be used by female patients who are or may become pregnant [<span class="Italics">seeWarnings and Precautions</span> (<a href="#s16">5</a>) and <span class="Italics">Use in Specific Populations </span>(<a href="#s74">8.1</a>, <a href="#s81">8.6</a>)].</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">There is an extremely high risk that severe <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> will result if pregnancy occurs while taking ABSORICA in any amount, even for short periods of time [<span class="Italics">seeWarnings and Precautions</span> (<a href="#s17">5.1</a>) and<span class="Italics"> Use in Specific Populations</span> (<a href="#s74">8.1</a>)].</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Potentially any fetus exposed during pregnancy can be affected [<span class="Italics">seeUse in Specific Populations</span>(<a href="#s74">8.1</a>)].</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">There are no accurate means of determining whether an exposed fetus has been affected [<span class="Italics">seeWarning and Precautions </span>(<a href="#s17">5.1</a>) and<span class="Italics"> Use in Specific Populations </span>(<a href="#s74">8.1</a>)].</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth defects</span> which have been documented following isotretinoin exposure include abnormalities of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands.  Cases of IQ scores less than 85 with or without other abnormalities have been reported.  There is an increased risk of <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span> and <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">premature births</span> have been reported [<span class="Italics">seeUse in Specific Populations</span>(<a href="#s74">8.1</a>)].</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Documented external abnormalities include:  skull abnormality; ear abnormalities (including <span class="product-label-link" type="condition" conceptid="381384" conceptname="Congenital absence of external ear">anotia</span>, micropinna, small or absent external auditory canals); eye abnormalities (including <span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmia</span>; facial dysmorphia; <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>).  Documented internal abnormalities include:  CNS abnormalities (including cerebral abnormalities, cerebellar malformation, <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephalus</span>, <span class="product-label-link" type="condition" conceptid="381114" conceptname="Microcephalus">microcephaly</span>, cranial nerve deficit); cardiovascular abnormalities; thymus gland abnormality; parathyroid hormone deficiency.  In some cases <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has occurred with certain abnormalities previously noted [<span class="Italics">seeUse in Specific Populations </span>(<a href="#s74">8.1</a>)].</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">If pregnancy does occur during the treatment of a female patient who is taking ABSORICA, ABSORICA must be discontinued immediately and she should be referred to an Obstetrician-Gynecologist experienced in reproductive toxicity for further evaluation and counseling [<span class="Italics">seeUse in Specific Populations </span>(<a href="#s74">8.1</a>)].</span></dd>
</dl>
<p><span class="Bold">Special Prescribing Requirements</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Because of the risk of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> and to minimize fetal exposure, ABSORICA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called iPLEDGEâ„¢. Under the ABSORICA REMS, prescribers, patients, pharmacies, and distributors must enroll and be registered in the program [<span class="Italics">seeWarnings and Precautions </span>(<a href="#s20">5.2</a>)].</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s2"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">ABSORICA is a retinoid indicated for the treatment of severe recalcitrant nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> in patients 12 years of age and older. <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">Nodules</span> are inflammatory lesions with a diameter of 5 mm or greater. The <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> may become suppurative or hemorrhagic. â€œSevere,â€? by definition, means â€œmanyâ€? as opposed to â€œfew or severalâ€? <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span>. <span class="Underline">Because of significant adverse reactions associated with its use, ABSORICA should be reserved for patients with multiple severe nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> who are unresponsive to conventional therapy, including systemic antibiotics</span>. In addition, ABSORICA is indicated only for those female patients who are not pregnant, because ABSORICA can cause severe <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> [see <span class="Italics">Contraindications</span> (<a href="#s14">4.1</a>)].</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-1.1"></a><p></p>
<p class="First"><span class="Underline">Limitations of Use</span></p>
<p>A single course of therapy for 15 to 20 weeks has been shown to result in complete and prolonged remission of disease in many patients. If a second course of therapy is needed, it should not be initiated until at least 8 weeks after completion of the first course, because experience with isotretinoin has shown that patients may continue to improve following treatment with isotretinoin. The optimal interval before retreatment has not been defined for patients who have not completed skeletal growth [<span class="Italics">seeWarnings and Precautions</span> (<a href="#s31">5.12</a>)].</p>
<p>As a part of the iPLEDGE program, ABSORICA may only be administered to patients enrolled in the program [<span class="Italics">seeWarnings and Precautions</span> (<a href="#s20">5.2</a>)].</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s4"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Healthcare professionals who prescribe ABSORICA must be certified in the iPLEDGE program and must comply with the required monitoring to ensure safe use of ABSORICA [see <span class="Italics">Warnings and Precautions</span> (<a href="#s20">5.2</a>)].</p>
<p>The required laboratory testing must be completed prior to dosing ABSORICA [see <span class="Italics">Dosage and Administration</span> (<a href="#s8">2.4</a>)].</p>
<p>Pregnancy Testing, and Contraceptive measures must be followed prior to dosing ABSORICA [<span class="Italics">seeUse in Specific Populations</span> (<a href="#s81">8.6</a>)].</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dosage</h2>
<p class="First">The recommended dosage range for ABSORICA is 0.5 to 1 mg/kg/day given in two divided doses without regard to meals for 15 to 20 weeks (see <a href="#_Reft1">Table 1</a>). To decrease the risk of esophageal irritation, patients should swallow the capsules with a full glass of liquid [<span class="Italics">seePatient Counseling Information</span> (<a href="#s102">17</a>)].</p>
<p>The safety of once daily dosing with ABSORICA has not been established. Once daily dosing is <span class="Bold">not</span> recommended.</p>
<a name="_Reft1"></a><table width="100%">
<caption><span>Table 1: ABSORICA Dosing by Body Weight (Based on Administration With or Without Food)</span></caption>
<col width="23%">
<col width="18%">
<col width="22%">
<col width="19%">
<col width="19%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Body Weight</span></p></td>
<td class="Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Total Daily (mg)</span></p></td>
</tr>
<tr>
<td align="center"><p class="First"><span class="Bold">Kilograms</span></p></td>
<td align="center"><p class="First"><span class="Bold">Pounds</span></p></td>
<td align="center"><p class="First"><span class="Bold">0.5 mg/kg</span></p></td>
<td align="center"><p class="First"><span class="Bold">1 mg/kg</span></p></td>
<td align="center"><p class="First"><span class="Bold">2 mg/kg</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center"><p class="First"> 40<br>50<br>60<br>70<br>80<br>90<br>100</p></td>
<td class="Botrule" align="center"><p class="First"> 88<br>110<br>132<br>154<br>176<br>198<br>220</p></td>
<td class="Botrule" align="center"><p class="First"> 20<br>25<br>30<br>35<br>40<br>45<br>50</p></td>
<td class="Botrule" align="center"><p class="First"> 40<br>50<br>60<br>70<br>80<br>90<br>100</p></td>
<td class="Botrule" align="center"><p class="First"> 80<br>100<br>120<br>140<br>160<br>180<br>200</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosage Range</h2>
<p class="First">In trials comparing 0.1, 0.5, and 1 mg/kg/day, it was found that all dosages provided initial clearing of disease, but there was a greater need for retreatment with the lower dosages. During treatment, the dose may be adjusted according to response of the disease and/or the appearance of clinical side effects, some of which may be dose-related. Adult patients whose disease is very severe with <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scarring</span> or is primarily manifested on the trunk may require dose adjustments up to 2 mg/kg/day, as tolerated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Duration of Use</h2>
<p class="First">A normal course of treatment is 15 â€“ 20 weeks. If the total <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodule</span> count has been reduced by more than 70% prior to completing 15 to 20 weeks of treatment, the drug may be discontinued. After a period of 2 months or more off therapy, and if warranted by persistent or recurring severe nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, a second course of therapy may be initiated. The optimal interval before retreatment has not been defined for patients who have not completed skeletal growth. Long-term use of ABSORICA, even in low doses, has not been studied, and is not recommended. It is important that ABSORICA be given at the recommended doses for no longer than the recommended duration. The effect of long-term use of ABSORICA on bone loss is unknown [<span class="Italics">seeWarnings and Precautions</span> (<a href="#s31">5.12</a>)].</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s8"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Laboratory Testing</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-2.4.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Testing </span></p>
<p>[<span class="Italics">SeeUse in Specific Populations</span> (<a href="#s81">8.6</a>)]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-2.4.2"></a><p></p>
<p class="First"><span class="Bold">Lipid Profile</span></p>
<p>Perform a fasting lipid profile including triglycerides prior to use of ABSORICA [<span class="Italics">seeWarnings and Precautions</span> (<a href="#s27">5.8</a>, <a href="#s41">5.15</a>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-2.4.3"></a><p></p>
<p class="First"><span class="Bold">Liver Function Test</span></p>
<p>Perform liver function tests prior to use of ABSORICA [<span class="Italics">seeWarnings and Precautions</span> (<a href="#s29">5.10</a>, <a href="#s41">5.15</a>)].</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s12"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">ABSORICA is available in 10 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg capsules.</p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">10 mg:</span> Dark yellow, opaque, capsule imprinted with black ink â€œ<span class="Bold">G 240</span>â€? on cap and â€œ<span class="Bold">10</span>â€? on the body</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">20 mg:</span> Red, opaque, capsule imprinted with black ink â€œ<span class="Bold">G 241</span>â€? on cap and â€œ<span class="Bold">20</span>â€? on the body</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">25 mg:</span> Green, opaque, capsule imprinted with white ink â€œ<span class="Bold">G 342</span>â€? on cap and â€œ<span class="Bold">25</span>â€? on the body</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">30 mg:</span> Brown, opaque, capsule imprinted with white ink â€œ<span class="Bold">G 242</span>â€? on cap and â€œ<span class="Bold">30</span>â€? on the body</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">35 mg:</span> Dark blue, opaque, capsule imprinted with white ink â€œ<span class="Bold">G 343</span>â€? on cap and â€œ<span class="Bold">35</span>â€? on the body</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">40 mg:</span> Brown and red, capsule imprinted with white ink â€œ<span class="Bold">G 325</span>â€? on cap and â€œ<span class="Bold">40</span>â€? on the body</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s13"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Pregnancy</h2>
<p class="First">ABSORICA can cause fetal harm when administered to a pregnant woman. Major congenital malformations, <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span>, and <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">premature births</span> have been documented following pregnancy exposure to isotretinoin in any amount and even for short periods of time. ABSORICA is contraindicated in females who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, treatment should be discontinued and the patient should be apprised of the potential hazard to the fetus [<span class="Italics">seeUse in Specific Populations</span> (<a href="#s74">8.1</a>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-4.2"></a><p></p>
<h2>4.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to this product (or Vitamin A, given the chemical similarity to isotretinoin) or to any of its components [<span class="Italics">seeWarnings and Precautions</span> (<a href="#s40">5.14</a>)].</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s16"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<p class="First">ABSORICA must not be used by female patients who are or may become pregnant. There is an extremely high risk that severe <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> will result if pregnancy occurs while taking ABSORICA in any amount, even for short periods of time.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Embryofetal Toxicity</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-5.1.1"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span></span></p>
<p>Major congenital malformations, <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span>, and <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">premature births</span> have been documented following pregnancy exposure to isotretinoin [<span class="Italics">seeUse in Specific Populations</span> (<a href="#s74">8.1</a>)].  Females of childbearing potential must comply with the pregnancy testing and contraception requirements described in the iPLEDGE program [<span class="Italics">seeWarnings and Precautions</span> (<a href="#s20">5.2</a>) and <span class="Italics">Use in Specific Populations</span> (<a href="#s81">8.6</a>)]. There are no accurate means of determining whether an exposed fetus has been affected.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-5.1.2"></a><p></p>
<p class="First"><span class="Underline">No Blood Donation</span></p>
<p>Patients must be informed not to donate blood during isotretinoin therapy and for 1 month following discontinuation of the drug because the blood might be given to a pregnant female patient whose fetus must not be exposed to isotretinoin.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-5.2"></a><p></p>
<h2>5.2 iPLEDGE Program</h2>
<p class="First">Because of the risk of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> and to minimize fetal exposure, ABSORICA is available only through a restricted program under a REMS called iPLEDGE. Under the ABSORICA REMS, prescribers, patients, pharmacies, and distributors must enroll and be registered in the program. ABSORICA must not be prescribed, dispensed or otherwise obtained through the internet or any other means outside of the iPLEDGE program. Only FDA-approved isotretinoin products must be distributed, prescribed, dispensed, and used.</p>
<p>Required components of the iPLEDGE Program are:</p>
<dl>
<dt>â€¢</dt>
<dd>ABSORICA must only be prescribed by prescribers who are registered and activated with the iPLEDGE program and agree to comply with the REMS requirements described in the booklets entitled <span class="Italics">The Guide to Best Practices for the iPLEDGE Program</span>, <span class="Italics">The iPLEDGE Program Prescriber Contraception Counseling Guide</span>, and <span class="Italics">Recognizing Psychiatric Disorders in Adolescents and Young Adults: A Guide for Prescribers of Isotretinoin</span>.</dd>
<dt>â€¢</dt>
<dd>Male patients and Female patients <span class="Underline">not</span> of childbearing potential: To obtain ABSORICA, these patients must understand the risks and benefits of ABSORICA, comply with the REMS requirements described in the booklet entitled <span class="Italics">The iPLEDGE Program Guide to Isotretinoin for Male Patients and Female Patients Who Cannot Get Pregnant</span>, and sign a Patient Information/Informed Consent form.</dd>
<dt>â€¢</dt>
<dd>Female patients of childbearing potential: ABSORICA is contraindicated in female patients who are or may become pregnant [<span class="Italics">seeContraindications</span> (<a href="#s14">4.1</a>)].</dd>
<dt>â€¢</dt>
<dd>Female patients of childbearing potential who are <span class="Underline">not</span> pregnant must understand the risks and benefits, comply with the REMS requirements described in the booklet entitled <span class="Italics">The iPLEDGE Program Guide to Isotretinoin for Female Patients Who Can Get Pregnant</span> and <span class="Italics">The iPLEDGE Program Birth Control Workbook</span> (including the pregnancy testing and contraception requirements [<span class="Italics">seeUse in Specific Populations</span> (<a href="#s81">8.6</a>) and <span class="Italics">Patient Counseling Information</span> (<a href="#s102">17</a>)]), and sign a Patient Information/Informed Consent form and Patient Information/Informed Consent About <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth Defects</span> form. Additionally, the patient must answer questions about the iPLEDGE program and pregnancy prevention monthly.</dd>
<dt>â€¢</dt>
<dd>Pharmacies that dispense ABSORICA must be registered and activated with iPLEDGE, must only dispense to patients who are authorized to receive ABSORICA, and agree to comply with the REMS requirements described in the booklet entitled <span class="Italics">The Pharmacist Guide for the iPLEDGE Program</span>.</dd>
<dt>â€¢</dt>
<dd>Female patients of childbearing potential must fill and pick up the prescription within 7 days of the specimen collection for the pregnancy test; male patients and female patients not of childbearing potential must fill and pick up the prescription within 30 days of the office visit.</dd>
<dt>â€¢</dt>
<dd>ABSORICA must only be dispensed in no more than a 30-day supply with a Medication Guide. Refills require a new prescription and a new authorization from the iPLEDGE system.</dd>
<dt>â€¢</dt>
<dd>Wholesalers and distributors that distribute ABSORICA must be registered with iPLEDGE and agree to comply with the REMS requirements.</dd>
</dl>
<p>If a pregnancy does occur during ABSORICA treatment, ABSORICA must be discontinued immediately. The patient should be referred to an obstetrician-gynecologist experienced in reproductive toxicity for further evaluation and counseling. Any suspected fetal exposure during or 1 month after ABSORICA therapy must be reported immediately to the FDA via the MedWatch telephone number 1-800-FDA-1088 and also to the iPLEDGE pregnancy registry at 1-866-495-0654 or via the internet (<span class="Underline">www.ipledgeprogram.com</span>).</p>
<p>Further information, including a list of qualified pharmacies, is available at <span class="Underline">www.ipledgeprogram.com</span> or 1-866-495-0654.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Unacceptable Contraception</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-5.3.1"></a><p></p>
<p class="First"><span class="Bold">Micro-dosed Progesterone Preparations</span></p>
<p>Micro-dosed progesterone preparations (â€œminipillsâ€? that do not contain an estrogen) are an inadequate method of contraception during ABSORICA therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Psychiatric Disorders</h2>
<p class="First">Isotretinoin may cause <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> and, rarely, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span>, <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, and aggressive and/or <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">violent behaviors</span>. No mechanism of action has been established for these reactions [<span class="Italics">seeAdverse Reactions</span> (<a href="#s47">6.1</a>)]. Prescribers should read the brochure, <span class="Italics">Recognizing Psychiatric Disorders in Adolescents and Young Adults: A Guide for Prescribers of Isotretinoin.</span> Prescribers should be alert to the warning signs of psychiatric disorders to guide patients to receive the help they need. Therefore, prior to initiation of ABSORICA therapy, patients and family members should be asked about any history of psychiatric disorder, and at each visit during therapy patients should be assessed for symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, mood disturbance, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, or <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span> to determine if further evaluation may be necessary. Signs and symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, as described in the brochure (<span class="Italics">Recognizing Psychiatric Disorders in Adolescents and Young Adults</span>), include sad mood, hopelessness, feelings of guilt, worthlessness or helplessness, loss of pleasure or interest in activities, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, difficulty concentrating, change in sleep pattern, change in weight or appetite, suicidal thoughts or attempts, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, acting on dangerous impulses, and persistent physical symptoms unresponsive to treatment. Patients should stop ABSORICA and the patient or a family member should promptly contact their prescriber if the patient develops <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, mood disturbance, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, or <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, without waiting until the next visit. Discontinuation of ABSORICA therapy may be insufficient; further evaluation may be necessary. While such monitoring may be helpful, it may not detect all patients at risk. Patients may report mental health problems or family history of psychiatric disorders. These reports should be discussed with the patient and/or the patient's family. A referral to a mental health professional may be necessary. The physician should consider whether ABSORICA therapy is appropriate in this setting; for some patients the risks may outweigh the benefits of ABSORICA therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">Pseudotumor Cerebri</span></h2>
<p class="First">Isotretinoin use has been associated with cases of <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">benign intracranial hypertension</span>), some of which involved concomitant use of tetracyclines. Concomitant treatment with tetracyclines should therefore be avoided. Early signs and symptoms of <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span> include <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>. Patients with these symptoms should be screened for <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> and, if present, they should be told to discontinue ABSORICA immediately and be referred to a neurologist for further diagnosis and care [<span class="Italics">seeAdverse Reactions</span> (<a href="#s47">6.1</a>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First">There have been post-marketing reports of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> and severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> [e.g., <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> (SJS), <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN)] associated with isotretinoin use. These reactions may be serious and result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, life-threatening events, hospitalization, or <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>. Patients should be monitored closely for severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, and discontinuation of ABSORICA should be considered if warranted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">Acute pancreatitis</span> has been reported in isotretinoin-treated patients with either elevated or normal serum triglyceride levels. In rare instances, fatal <span class="product-label-link" type="condition" conceptid="4185268" conceptname="Acute hemorrhagic pancreatitis">hemorrhagic pancreatitis</span> has been reported. ABSORICA should be stopped if <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> cannot be controlled at an acceptable level or if symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Lipid Abnormalities</h2>
<p class="First">Elevations of serum triglycerides in excess of 800 mg/dL have been reported in patients treated with isotretinoin. Marked elevations of serum triglycerides were reported in approximately 25% of patients receiving isotretinoin in clinical trials. In addition, approximately 15% developed a decrease in high-density lipoproteins and about 7% showed an increase in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels. In clinical trials, the effects of triglycerides, HDL and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> were reversible upon cessation of isotretinoin therapy. Some patients have been able to reverse triglyceride elevation by reduction in weight, restriction of dietary fat and alcohol, and reduction in the dose while continuing isotretinoin.</p>
<p>Blood lipid determinations should be performed before ABSORICA is given and then at intervals until the lipid response to ABSORICA is established, which usually occurs within 4 weeks. Especially careful consideration must be given to risk/benefit for patients who may be at high risk of triglyceridemia during ABSORICA therapy (patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, increased alcohol intake, <span class="product-label-link" type="condition" conceptid="437530" conceptname="Disorder of lipid metabolism">lipid metabolism disorder</span> or familial history of <span class="product-label-link" type="condition" conceptid="437530" conceptname="Disorder of lipid metabolism">lipid metabolism disorder</span>). If ABSORICA therapy is instituted, more frequent checks of serum values for lipids and/or blood sugar are recommended [<span class="Italics">seeWarnings and Precautions</span> (<a href="#s41">5.15</a>)].</p>
<p>The cardiovascular consequences of <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> associated with isotretinoin are unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Hearing Impairment</h2>
<p class="First">Impaired hearing has been reported in patients taking isotretinoin; in some cases, the hearing impairment has been reported to persist after therapy has been discontinued. Mechanism(s) and causality for this reaction have not been established. Patients who experience <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> or hearing impairment should discontinue ABSORICA treatment and be referred for specialized care for further evaluation [<span class="Italics">seeAdverse Reactions</span> (<a href="#s47">6.1</a>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Hepatotoxicity</h2>
<p class="First">Clinical <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> considered to be possibly or probably related to isotretinoin therapy has been reported. Additionally, mild to moderate elevations of liver enzymes have been observed in approximately 15% of individuals treated during clinical trials with isotretinoin, some of which normalized with dosage reduction or continued administration of the drug. If normalization does not readily occur or if <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> is suspected during treatment with ABSORICA, the drug should be discontinued and the etiology further investigated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-5.11"></a><p></p>
<h2>5.11 <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">Inflammatory Bowel Disease</span></h2>
<p class="First">Isotretinoin has been associated with <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span> (including regional <span class="product-label-link" type="condition" conceptid="4203614" conceptname="Ileitis">ileitis</span>) in patients without a prior history of intestinal disorders. In some instances, symptoms have been reported to persist after isotretinoin treatment has been stopped. Patients experiencing <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span> or severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> should discontinue ABSORICA immediately [<span class="Italics">seeAdverse Reactions</span> (<a href="#s47">6.1</a>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Skeletal Abnormalities</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-5.12.1"></a><p></p>
<p class="First"><span class="Bold">Bone Mineral Density Changes</span></p>
<p>Isotretinoin may have a negative effect on bone mineral density (BMD) in some patients. In a clinical trial of ABSORICA and a generic product of Accutane<span class="Sup">Â®</span> (isotretinoin), 27/306 (8.8%) of adolescents had BMD declines, defined as â‰¥ 4% lumbar spine or total hip, or â‰¥ 5% femoral neck, during the 20 week treatment period. Repeat scans conducted within 2-3 months after the post-treatment scan showed no recovery of BMD. Longer term data at 4-11 months showed that 3 out of 7 patients had total hip and femoral neck BMD below pre-treatment baseline, and 2 others did not show the increase in BMD above baseline expected in this adolescent population. Therefore, physicians should use caution when prescribing ABSORICA to patients with a history of childhood <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> conditions, <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span>, or other disorders of bone metabolism. This would include patients diagnosed with <span class="product-label-link" type="condition" conceptid="436675" conceptname="Anorexia nervosa">anorexia nervosa</span> and those who are on chronic drug therapy that causes drug-induced <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>/<span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span> and/or affects vitamin D metabolism, such as systemic corticosteroids and any anticonvulsant [<span class="Italics">see Use in Specific Populations</span> (<a href="#s79">8.4</a>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-5.12.2"></a><p></p>
<p class="First"><span class="Bold">Musculoskeletal Abnormalities</span></p>
<p>Approximately 16% of patients treated with isotretinoin in a clinical trial developed musculoskeletal symptoms (including <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>) during treatment. In general, these symptoms were mild to moderate, but occasionally required discontinuation of the drug.</p>
<p>In a trial of pediatric patients treated with isotretinoin, approximately 29% (104/358) developed <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>. <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span> was severe in 13.5% (14/104) of the cases and occurred at a higher frequency in female patients than male patients. <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgias</span> were experienced in 22% (79/358) of pediatric patients. <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgias</span> were severe in 7.6% (6/79) of patients. Appropriate evaluation of the musculoskeletal system should be done in patients who present with these symptoms during or after a course of ABSORICA. Consideration should be given to discontinuation of ABSORICA if any significant abnormality is found.</p>
<p>There have been spontaneous reports of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, <span class="product-label-link" type="condition" conceptid="4195039" conceptname="Osteopenia">osteopenia</span>, bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> and/or delayed healing of bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> in patients while on therapy with isotretinoin or following cessation of therapy with isotretinoin. While causality to isotretinoin has not been established, an effect cannot be ruled out.</p>
<p>Patients may be at an increased risk when participating in sports with repetitive impact where the risks of <span class="product-label-link" type="condition" conceptid="4167097" conceptname="Spondylolisthesis">spondylolisthesis</span> with and without pars <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> and hip growth plate injures in early and late adolescence are known.</p>
<p>Effects of multiple courses of isotretinoin on the developing musculoskeletal system are unknown. There is some evidence that long-term, high-dose, or multiple courses of therapy with isotretinoin have more of an effect than a single course of therapy on the musculoskeletal system.</p>
<p>Longer term effects have not been studied. It is important that ABSORICA be given at the recommended doses for no longer than the recommended duration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-5.12.3"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="72715" conceptname="Exostosis">Hyperostosis</span></span></p>
<p>A high prevalence of skeletal <span class="product-label-link" type="condition" conceptid="72715" conceptname="Exostosis">hyperostosis</span> was noted in clinical trials for disorders of keratinization with a mean dose of 2.24 mg/kg/day of isotretinoin. Additionally, skeletal <span class="product-label-link" type="condition" conceptid="72715" conceptname="Exostosis">hyperostosis</span> was noted in 6 of 8 patients in a prospective trial of disorders of keratinization. Minimal skeletal <span class="product-label-link" type="condition" conceptid="72715" conceptname="Exostosis">hyperostosis</span> and calcification of ligaments and tendons have also been observed by x-ray in prospective trials of nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with a single course of therapy at recommended doses. The skeletal effects of multiple isotretinoin treatment courses for <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> are unknown.</p>
<p>In a clinical trial of 217 pediatric patients (12 to 17 years) with severe recalcitrant nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="72715" conceptname="Exostosis">hyperostosis</span> was not observed after 16 to 20 weeks of treatment with approximately 1 mg/kg/day of isotretinoin given in two divided doses. <span class="product-label-link" type="condition" conceptid="72715" conceptname="Exostosis">Hyperostosis</span> may require a longer time frame to appear. The clinical course and significance remain unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-5.12.4"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4232188" conceptname="Premature epiphyseal closure">Premature Epiphyseal Closure</span></span></p>
<p>There are spontaneous literature reports of <span class="product-label-link" type="condition" conceptid="4232188" conceptname="Premature epiphyseal closure">premature epiphyseal closure</span> in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients receiving recommended doses of isotretinoin. The effect of multiple courses of isotretinoin on epiphyseal closure is unknown.</p>
<p>In a 20-week clinical trial that included 289 adolescents on ABSORICA or a generic product of Accutane<span class="Sup">Â®</span> (isotretinoin) who had hand radiographs taken to assess bone age, a total of 9 (3.11%) patients had bone age changes that were clinically significant and for which a drug-related effect cannot be excluded.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-5.13"></a><p></p>
<h2>5.13 Ocular Abnormalities</h2>
<p class="First">Visual problems should be carefully monitored. All ABSORICA patients experiencing visual difficulties should discontinue ABSORICA treatment and have an ophthalmological examination [<span class="Italics">see Adverse Reactions</span> (<a href="#s47">6.1</a>)].</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-5.13.1"></a><p></p>
<p class="First"><span class="Bold">Corneal Opacities</span></p>
<p>Corneal opacities have occurred in patients receiving isotretinoin for <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> and more frequently when higher drug dosages were used in patients with disorders of keratinization. The corneal opacities that have been observed in clinical trial patients treated with isotretinoin have either completely resolved or were resolving at follow-up 6 to 7 weeks after discontinuation of the drug [<span class="Italics">see Adverse Reactions </span>(<a href="#s47">6.1</a>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s38"></a><a name="section-5.13.2"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="374037" conceptname="Night blindness">Decreased Night Vision</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="374037" conceptname="Night blindness">Decreased night vision</span> has been reported during isotretinoin therapy and in some instances the event has persisted after therapy was discontinued. Because the onset in some patients was sudden, patients should be advised of this potential problem and warned to be cautious when driving or operating any vehicle at night.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-5.13.3"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">Dry Eye</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">Dry eye</span> has been reported in subjects during isotretinoin therapy. Patients who wear contact lenses may have trouble wearing them while on ABSORICA treatment and afterwards.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-5.14"></a><p></p>
<h2>5.14 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> and other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> have been reported in isotretinoin-treated patients. Cutaneous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> and serious cases of <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">allergic vasculitis</span>, often with <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> (<span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruises</span> and red patches) of the extremities and extracutaneous involvement (including renal) have been reported. Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> necessitates discontinuation of therapy and appropriate medical management.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-5.15"></a><p></p>
<h2>5.15 Laboratory Monitoring for Adverse Reactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-5.15.1"></a><p></p>
<p class="First"><span class="Bold">Lipids Test</span></p>
<p>Pretreatment and follow-up blood lipids should be obtained under fasting conditions. After consumption of alcohol, at least 36 hours should elapse before these determinations are made. It is recommended that these tests be performed at weekly or biweekly intervals until the lipid response to ABSORICA is established. The incidence of <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> is 1 patient in 4 on isotretinoin [<span class="Italics">see Warnings and Precautions</span> (<a href="#s27">5.8</a>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-5.15.2"></a><p></p>
<p class="First"><span class="Bold">Liver Function Test</span></p>
<p>Since elevations of liver enzymes have been observed during clinical trials, and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> has been reported in patients on isotretinoin, pretreatment and follow-up liver function tests should be performed at weekly or biweekly intervals until the response to ABSORICA has been established [<span class="Italics">see Warnings and Precautions</span> (<a href="#s29">5.10</a>)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-5.15.3"></a><p></p>
<p class="First"><span class="Bold">Glucose</span></p>
<p>Some patients receiving isotretinoin have experienced problems in the control of their blood sugar. In addition, new cases of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> have been diagnosed during isotretinoin therapy, although no causal relationship has been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-5.15.4"></a><p></p>
<p class="First"><span class="Bold">CPK</span></p>
<p>Some patients undergoing vigorous physical activity while on isotretinoin therapy have experienced elevated CPK levels; however, the clinical significance is unknown. There have been rare postmarketing reports of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, some associated with strenuous physical activity. In an isotretinoin clinical trial of 924 patients, marked elevations in CPK (â‰¥350 U/L) were observed in approximately 24% of patients. In another clinical trial of 217 pediatric patients (12 â€“ 17 years) elevations in CPK were observed in 12% of patients, including those undergoing strenuous physical activity in association with reported musculoskeletal adverse events such as <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="444130" conceptname="Injury of foot">limb injury</span>, or muscle <span class="product-label-link" type="condition" conceptid="30234" conceptname="Neck sprain">sprain</span>. In these patients, approximately half of the CPK elevations returned to normal within 2 weeks and half returned to normal within 4 weeks. No cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> were reported in this clinical trial.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s46"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions with ABSORICA or other isotretinoin products are described in more detail in other sections of the labeling:</p>
<dl>
<dt>â€¢</dt>
<dd>Embryofetal Toxicity [<span class="Italics">see Warnings and Precautions</span> (<a href="#s17">5.1</a>)]</dd>
<dt>â€¢</dt>
<dd>Psychiatric Disorders [<span class="Italics">see Warnings and Precautions</span> (<a href="#s23">5.4</a>)]</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">Pseudotumor Cerebri</span> [<span class="Italics">see Warnings and Precautions</span> (<a href="#s24">5.5</a>)]</dd>
<dt>â€¢</dt>
<dd>Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span> [<span class="Italics">see Warnings and Precautions</span> (<a href="#s25">5.6</a>)]</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> [<span class="Italics">see Warnings and Precautions</span> (<a href="#s26">5.7</a>)]</dd>
<dt>â€¢</dt>
<dd>Lipid Abnormalities [<span class="Italics">see Warnings and Precautions</span> (<a href="#s27">5.8</a>)]</dd>
<dt>â€¢</dt>
<dd>Hearing Impairment [<span class="Italics">see Warnings and Precautions</span> (<a href="#s28">5.9</a>)]</dd>
<dt>â€¢</dt>
<dd>Hepatotoxicity [<span class="Italics">see Warnings and Precautions</span> (<a href="#s29">5.10</a>)]</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">Inflammatory Bowel Disease</span> [<span class="Italics">see Warnings and Precautions</span> (<a href="#s30">5.11</a>)]</dd>
<dt>â€¢</dt>
<dd>Skeletal Abnormalities [<span class="Italics">see Warnings and Precautions</span> (<a href="#s31">5.12</a>)]</dd>
<dt>â€¢</dt>
<dd>Ocular Abnormalities [<span class="Italics">see Warnings and Precautions</span> (<a href="#s36">5.13</a>)]</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> [<span class="Italics">see Warnings and Precautions</span> (<a href="#s40">5.14</a>)]</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of ABSORICA cannot be directly compared to rates in clinical trials of other drugs and may not reflect the rates observed in practice.</p>
<p>The adverse reactions listed below reflect both clinical experience with ABSORICA, and consider other adverse reactions that are known from clinical trials and the post-marketing surveillance with oral isotretinoin. The relationship of some of these events to isotretinoin therapy is unknown. Many of the side effects and adverse events seen in patients receiving isotretinoin are similar to those described in patients taking very high doses of vitamin A (dryness of the skin and mucous membranes, e.g., of the lips, nasal passage, and eyes).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold">Dose Relationship</span></p>
<p><span class="product-label-link" type="condition" conceptid="4301764" conceptname="Cheilitis">Cheilitis</span> and <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> are adverse reactions that are usually dose related. Most adverse reactions reported in clinical trials with isotretinoin were reversible when therapy was discontinued; however, some persisted after cessation of therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s49"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold">Body as a Whole</span></p>
<p>The following adverse reactions have been reported in a clinical trial conducted with ABSORICA and a generic product of Accutane<span class="Sup">Â®</span> (isotretinoin): <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. In addition to the above adverse reactions, the following adverse reactions have been reported with isotretinoin: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, including <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, systemic <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Bold">Cardiovascular</span></p>
<p>The following adverse reactions have been reported with isotretinoin: vascular thrombotic disease, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Bold">Endocrine/Metabolism and Nutritional </span></p>
<p>The following adverse reactions have been reported in a clinical trial conducted with ABSORICA and a generic product of Accutane<span class="Sup">Â®</span> (isotretinoin): <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="4093974" conceptname="Weight fluctuates">weight fluctuation</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidaemia</span>. In addition to the above adverse reactions, the following adverse reactions have been reported with isotretinoin: <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, alterations in blood sugar.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-6.1.5"></a><p></p>
<p class="First"><span class="Bold">Gastrointestinal</span></p>
<p>The following adverse reactions have been reported in a clinical trial conducted with ABSORICA and a generic product of Accutane<span class="Sup">Â®</span> (isotretinoin): <span class="product-label-link" type="condition" conceptid="4039954" conceptname="Cheilosis">lip dry</span>, <span class="product-label-link" type="condition" conceptid="4039954" conceptname="Cheilosis">chapped lips</span>, <span class="product-label-link" type="condition" conceptid="4301764" conceptname="Cheilitis">cheilitis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. In addition to the above adverse reactions, the following adverse reactions have been reported with isotretinoin: <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the gums, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>/<span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulceration</span>, <span class="product-label-link" type="condition" conceptid="4203614" conceptname="Ileitis">ileitis</span>, and other nonspecific <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-6.1.6"></a><p></p>
<p class="First"><span class="Bold">Hematologic</span></p>
<p>The following adverse reactions have been reported with isotretinoin: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, rare reports of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-6.1.7"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span> </span></p>
<p>The following adverse reactions have been reported in a clinical trial conducted with ABSORICA and a generic product of Accutane<span class="Sup">Â®</span> (isotretinoin): <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4265426" conceptname="Hordeolum">hordeolum</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>. In addition to the above adverse reactions, the following adverse reaction has been reported with isotretinoin: <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (including disseminated herpes simplex).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-6.1.8"></a><p></p>
<p class="First"><span class="Bold">Laboratory Abnormalities</span></p>
<p>The following changes in laboratory tests have been noted in a clinical trial conducted with ABSORICA and a generic product of Accutane<span class="Sup">Â®</span> (isotretinoin): <span class="product-label-link" type="condition" conceptid="4294804" conceptname="Creatine kinase">blood creatine phosphokinase</span> (CPK) increased, blood triglycerides increased, <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (SGPT) increased, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) increased, gamma-glutamyltransferase (GGTP) increased, blood <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> increased, low density lipoprotein (LDL) increased, white blood cell count decreased, blood alkaline phosphatase increased, blood bilirubin increased, blood glucose increased, high density lipopoprotein (HDL) decreased,  bone  mineral density decreased. In addition to the above adverse reactions, the following adverse reactions have been reported with isotretinoin: increased LDH, elevation of fasting blood sugar, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, decreases in red blood cell parameters, decreases in white blood cell counts (including severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and rare reports of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>), <span class="product-label-link" type="condition" conceptid="4013526" conceptname="ESR raised">elevated sedimentation rates</span>, elevated platelet counts, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, white cells in the urine, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, microscopic or gross <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s56"></a><a name="section-6.1.9"></a><p></p>
<p class="First"><span class="Bold">Musculoskeletal and Connective Tissue</span></p>
<p>The following adverse reactions have been reported in a clinical trial conducted with ABSORICA and a generic product of Accutane<span class="Sup">Â®</span> (isotretinoin): decreases in bone mineral density, musculoskeletal symptoms (sometimes severe) including <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, athralgia, musculoskeletal <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">pain in extremity</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">musculoskeletal stiffness</span> [<span class="Italics">seeWarnings and Precautions</span> (<a href="#s31">5.12</a>)]. In addition to the above adverse reactions, the following adverse reactions have been reported with isotretinoin: skeletal <span class="product-label-link" type="condition" conceptid="72715" conceptname="Exostosis">hyperostosis</span>, calcification of tendons and ligaments, <span class="product-label-link" type="condition" conceptid="4232188" conceptname="Premature epiphyseal closure">premature epiphyseal closure</span>, <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendonitis</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, transient <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the chest, and rare reports of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s57"></a><a name="section-6.1.10"></a><p></p>
<p class="First"><span class="Bold">Neurological</span></p>
<p>The following adverse reactions have been reported in a clinical trial conducted with ABSORICA and a generic product of Accutane<span class="Sup">Â®</span> (isotretinoin): <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>. In addition to the above adverse reactions, other adverse reactions reported with isotretinoin include: <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s58"></a><a name="section-6.1.11"></a><p></p>
<p class="First"><span class="Bold">Psychiatric</span></p>
<p>The following adverse reactions have been reported in clinical trials conducted with ABSORICA and a generic product of Accutane<span class="Sup">Â®</span> (isotretinoin): <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attack</span>, <span class="product-label-link" type="condition" conceptid="4327815" conceptname="Feeling angry">anger</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">violent behaviors</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span>. In addition to the above adverse reactions, the following adverse reactions have been reported with isotretinoin: <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span>, <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> and <span class="product-label-link" type="condition" conceptid="4164151" conceptname="Auditory hallucinations">hallucination auditory</span>. Of the patients reporting <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, some reported that the <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> subsided with discontinuation of therapy and recurred with reinstitution of therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s59"></a><a name="section-6.1.12"></a><p></p>
<p class="First"><span class="Bold">Reproductive System </span></p>
<p>The following adverse reaction has been reported with isotretinoin: abnormal menses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-6.1.13"></a><p></p>
<p class="First"><span class="Bold">Respiratory</span></p>
<p>The following adverse reactions have been reported in a clinical trial conducted with ABSORICA and a generic product of Accutane<span class="Sup">Â®</span> (isotretinoin): <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4171214" conceptname="Nasal mucosa dry">nasal dryness</span>. In addition to the above adverse reactions, the following adverse reactions have been reported with isotretinoin: <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasms</span> (with or without a history of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>), <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">voice alteration</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s61"></a><a name="section-6.1.14"></a><p></p>
<p class="First"><span class="Bold">Skin and Subcutaneous Tissue</span></p>
<p>The following adverse reactions have been reported in a clinical trial conducted with ABSORICA and a generic product of Accutane<span class="Sup">Â®</span> (isotretinoin): <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">dermatitis contact</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, sunburn, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>. In addition to the above adverse reactions, the following adverse reactions have been reported with isotretinoin: <span class="product-label-link" type="condition" conceptid="4263196" conceptname="Acne fulminans">acne fulminans</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> (which in some cases persists), <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="4171214" conceptname="Nasal mucosa dry">dry nose</span>, <span class="product-label-link" type="condition" conceptid="4033043" conceptname="Eruptive xanthoma">eruptive xanthomas</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, fragility of skin, hair abnormalities, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, hyperpigmentation and hypopigmentation, <span class="product-label-link" type="condition" conceptid="4336254" conceptname="Dystrophia unguium">nail dystrophy</span>, <span class="product-label-link" type="condition" conceptid="137057" conceptname="Paronychia">paronychia</span>, <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> of palms and soles, photoallergic/photosensitizing reactions, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4308074" conceptname="Pyogenic granuloma">pyogenic granuloma</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (including facial <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span>, and <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>), <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, sunburn susceptibility increased, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> (including Wegener's granulomatosis), abnormal <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing (delayed healing or exuberant granulation tissue with crusting).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s62"></a><a name="section-6.1.15"></a><p></p>
<p class="First"><span class="Bold">Special Senses</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s63"></a><a name="section-6.1.15.1"></a><p></p>
<p class="First"><span class="Bold">Hearing:</span> The following adverse reactions have been reported with isotretinoin: <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> and hearing impairment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s64"></a><a name="section-6.1.15.2"></a><p></p>
<p class="First"><span class="Bold">Ocular:</span> The following adverse reactions have been reported in clinical trials conducted with ABSORICA and a generic product of Accutane<span class="Sup">Â®</span> (isotretinoin): <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>, <span class="product-label-link" type="condition" conceptid="376402" conceptname="Low vision, one eye">visual acuity reduced</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">vision blurred</span>, eye pruritis, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="4322318" conceptname="Eye strain">asthenopia</span>, <span class="product-label-link" type="condition" conceptid="374037" conceptname="Night blindness">decreased night vision</span>, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">ocular hyperemia</span>, increased <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, and <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>. In addition to the above adverse reactions, the following adverse reactions have been reported with isotretinoin: corneal opacities, <span class="product-label-link" type="condition" conceptid="374037" conceptname="Night blindness">decreased night vision</span> which may persist, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, color vision disorder, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, eyelid <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span>, photobia, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s65"></a><a name="section-6.1.15.3"></a><p></p>
<p class="First"><span class="Bold">Renal and Urinary</span></p>
<p>The following adverse reactions have been reported in clinical trials conducted with isotretinoin: <span class="product-label-link" type="condition" conceptid="4263367" conceptname="Glomerulonephritis">glomerulonephritis</span>, nonspecific urogenital findings.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s66"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s67"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Vitamin A</h2>
<p class="First">ABSORICA is closely related to vitamin A. Therefore, the use of both vitamin A and ABSORICA at the same time may lead to vitamin A side effects. Patients should be advised against taking vitamin supplements containing Vitamin A to avoid additive toxic effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s68"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Tetracyclines</h2>
<p class="First">Concomitant treatment with ABSORICA and tetracyclines should be avoided because isotretinoin use has been associated with a number of cases of <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">benign intracranial hypertension</span>), some of which involved concomitant use of tetracyclines.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s69"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Phenytoin</h2>
<p class="First">Isotretinoin has not been shown to alter the pharmacokinetics of phenytoin in a trial in seven healthy volunteers. These results are consistent with the in vitro finding that neither isotretinoin nor its metabolites induce or inhibit the activity of the CYP2C9 human hepatic P450 enzyme. Phenytoin is known to cause <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span>. No formal clinical trials have been conducted to assess if there is an interactive effect on bone loss between phenytoin and isotretinoin. Therefore, caution should be exercised when using these drugs together.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s70"></a><a name="section-7.4"></a><p></p>
<h2>7.4 St. John's Wort</h2>
<p class="First">Isotretinoin use is associated with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> in some patients. Patients should be prospectively cautioned not to self-medicate with the herbal supplement St. John's Wort because a possible interaction has been suggested with hormonal contraceptives based on reports of breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> on oral contraceptives shortly after starting St. John's Wort. Pregnancies have been reported by users of combined hormonal contraceptives who also used some form of St. John's Wort.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s71"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Systemic Corticosteroids</h2>
<p class="First">Systemic corticosteroids are known to cause <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. No formal clinical trials have been conducted to assess if there is an interactive effect on bone loss between systemic corticosteroids and isotretinoin. Therefore, caution should be exercised when using these drugs together.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s72"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Norethindrone/ethinyl estradiol</h2>
<p class="First">In a trial of 31 premenopausal female patients with severe recalcitrant nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> receiving Norethindrone/ethinyl estradiol as an oral contraceptive agent, isotretinoin at the recommended dose of 1 mg/kg/day, did not induce clinically relevant changes in the pharmacokinetics of ethinyl estradiol and norethindrone and in the serum levels of progesterone, follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Prescribers are advised to consult the package insert of medication administered concomitantly with hormonal contraceptives, since some medications may decrease the effectiveness of these birth control products.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s73"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s74"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category X [<span class="Italics">see Contraindications (4) and Warnings and Precautions (5.1)</span>].</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s75"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Underline">Risk Summary</span></p>
<p>ABSORICA is contraindicated during pregnancy because isotretinoin can cause can cause fetal harm when administered to a pregnant woman. There is an increased risk of major congenital malformations, <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortions</span>, and <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">premature births</span> following isotretinoin exposure during pregnancy in humans. If this drug is used during pregnancy, or if the patient becomes pregnant while taking the drug, the patient should be apprised of the potential hazard to a fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s76"></a><a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Underline">Clinical Considerations</span></p>
<p>If pregnancy does occur during treatment of a female patient who is taking ABSORICA, ABSORICA must be discontinued immediately and she should be referred to an obstetrician-gynecologist experienced in reproductive toxicity for further evaluation and counseling.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s77"></a><a name="section-8.1.3"></a><p></p>
<p class="First"><span class="Underline">Human Data</span></p>
<p>Major congenital malformations that have been documented following isotretinoin exposure include malformations of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands. External malformations include: skull; ear (including <span class="product-label-link" type="condition" conceptid="381384" conceptname="Congenital absence of external ear">anotia</span>, micropinna, small or absent external auditory canals); eye (including <span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmia</span>); facial dysmorphia and <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>. Internal abnormalities include: CNS (including cerebral and cerebellar malformations, <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephalus</span>, <span class="product-label-link" type="condition" conceptid="381114" conceptname="Microcephalus">microcephaly</span>, cranial nerve deficit); cardiovascular; thymus gland; parathyroid hormone deficiency. In some cases <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has occurred as a result of the malformations.</p>
<p>Isotretinoin is found in the semen of male patients taking isotretinoin, but the amount delivered to a female partner would be about one million times lower than an oral dose of 40 mg. While the no-effect limit for isotretinoin induced embryopathy is unknown and 20 years of post-marketing reports include four reports with isolated defects compatible with features of retinoid exposed fetuses, two of these reports were incomplete and two had other possible explanations for the defects observed.</p>
<p>Cases of IQ scores less than 85 with or without other abnormalities have been reported. An increased risk of <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span> and <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">premature births</span> have been documented with isotretinoin exposure during pregnancy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s78"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is present in human milk. Because many drugs are present in human milk and because of the potential for serious adverse reactions in nursing infants from ABSORICA, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s79"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The use of ABSORICA in pediatric patients less than 12 years of age has not been studied. The use of ABSORICA for the treatment of severe recalcitrant nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> in pediatric patients ages 12 to 17 years should be given careful consideration, especially for those patients where a known metabolic or structural bone disease exists [<span class="Italics">see Warnings and Precautions</span> (<a href="#s31">5.12</a>)]. Use of ABSORICA in this age group for severe recalcitrant nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> is supported by evidence from a clinical trial of ABSORICA compared to a generic product of Accutane<span class="Sup">Â®</span> (isotretinoin) in 397 pediatric patients (12 to 17 years). Results from this trial demonstrated that both ABSORICA and the other isotretinoin drug product, at a dose of 1Â mg/kg/day given in two divided doses, was effective in treating severe recalcitrant nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> in pediatric patients.</p>
<p>In trials with isotretinoin, adverse reactions reported in pediatric patients were similar to those described in adults except for the increased incidence of <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (both of which were sometimes severe) and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> in pediatric patients. In a trial of pediatric patients treated with isotretinoin, approximately 29% (104/358) developed <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>. <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span> was severe in 13.5% (14/104) of the cases and occurred at a higher frequency in female patients than male patients. <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgias</span> were experienced in 22% (79/358) of pediatric patients. <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgias</span> were severe in 7.6% (6/79) of patients. Appropriate evaluation of the musculoskeletal system should be done in patients who present with these symptoms during or after a course of ABSORICA. Consideration should be given to discontinuation of ABSORICA if any significant abnormality is found.</p>
<p>The effect on bone mineral density (BMD) of a 20-week course of therapy with ABSORICA or a generic product of Accutane<span class="Sup">Â®</span> (isotretinoin) was evaluated in a double-blind, randomized clinical trial involving 396 adolescents with severe recalcitrant nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> (mean age 15.4, range 12-17, 80% males). Following 20 weeks of treatment, there were no statistically significant differences between the treatment groups. The mean changes in BMD from baseline for the overall trial population were 1.8% for lumbar spine, -0.1% for total hip and -0.3% for femoral neck. Mean BMD Z-scores declined from baseline at each of these sites (-0.053, -0.109 and -0.104 respectively). Out of 306 adolescents, 27 (8.8%) had clinically significant BMD declines defined as â‰¥4% lumbar spine or total hip, or â‰¥5% femoral neck, including 2 subjects for lumbar spine, 17 for total hip and 20 for femoral neck. Repeat DXA scans within 2-3 months after the post treatment scan showed no recovery of BMD. Longer-term follow up at 4-11 months showed that 3 out of 7 patients had total hip and femoral neck BMD below pre-treatment baseline, and 2 others did not show the increase in BMD above baseline expected in this adolescent population. The significance of these changes in regard to long-term bone health and future <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> risk is unknown [<span class="Italics">see Warnings and Precautions</span> (<a href="#s31">5.12</a>)].</p>
<p>In an open-label clinical trial (N=217) of a single course of therapy with isotretinoin for adolescents with severe recalcitrant nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, bone density measurements at several skeletal sites were not significantly decreased (lumbar spine change &gt;-4% and total hip change &gt;-5%) or were increased in the majority of patients. One patient had a decrease in lumbar spine bone mineral density &gt;4% based on unadjusted data. Sixteen (7.9%) patients had decreases in lumbar spine bone mineral density &gt;4%, and all the other patients (92%) did not have significant decreases or had increases (adjusted for body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index). Nine patients (4.5%) had a decrease in total hip bone mineral density &gt;5% based on unadjusted data. Twenty-one (10.6%) patients had decreases in total hip bone mineral density &gt;5%, and all the other patients (89%) did not have significant decreases or had increases (adjusted for body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index). Follow-up trials performed in 8 of the patients with decreased bone mineral density for up to 11 months thereafter demonstrated increasing bone density in 5 patients at the lumbar spine, while the other 3 patients had lumbar spine bone density measurements below baseline values. Total hip bone mineral densities remained below baseline (range âˆ’1.6% to âˆ’7.6%) in 5 of 8 patients (62.5%).</p>
<p>In a separate open-label extension trial of 10 patients, ages 13 to 18 years, who started a second course of isotretinoin 4 months after the first course, two patients showed a decrease in mean lumbar spine bone mineral density up to 3.25%.</p>
<p>There are spontaneous literature reports of <span class="product-label-link" type="condition" conceptid="4232188" conceptname="Premature epiphyseal closure">premature epiphyseal closure</span> in <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients receiving recommended doses of isotretinoin. The effect of multiple courses of isotretinoin on epiphyseal closure is unknown. In a 20-week clinical trial that included 289 adolescents who had hand radiographs taken to assess bone age, a total of 9 patients had bone age changes that were clinically significant and for which a drug-related effect cannot be excluded [<span class="Italics">see Warnings and Precautions</span> (<a href="#s31">5.12</a>)].</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s80"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical trials of ABSORICA did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. Although reported clinical experience has not identified differences in responses between elderly and younger patients, effects of aging might be expected to increase some risks associated with ABSORICA therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s81"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Females of Childbearing Potential</h2>
<p class="First">All females of childbearing potential must comply with the iPLEDGE program requirements [<span class="Italics">see Warnings and Precautions</span> (<a href="#s20">5.2</a>)].</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s82"></a><a name="section-8.5.1"></a><p></p>
<p class="First"><span class="Underline">Pregnancy Testing</span></p>
<p>ABSORICA must only be prescribed to female patients who are known not to be pregnant as confirmed by a negative CLIA-certified laboratory conducted pregnancy test. Female patients of childbearing potential must have had two negative urine or serum pregnancy tests with a sensitivity of at least 25 mIU/mL before receiving the initial ABSORICA prescription. The first test (a screening test) is obtained by the prescriber when the decision is made to pursue qualification of the patient for ABSORICA. The second pregnancy test (a confirmation test) must be done in a CLIA-certified laboratory. The interval between the two tests must be at least 19 days.</p>
<dl>
<dt>â€¢</dt>
<dd>For patients with regular menstrual cycles, perform the second pregnancy test during the first 5 days of the menstrual period immediately preceding the beginning of ABSORICA therapy and after the patient has used 2 forms of contraception for 1 month.</dd>
<dt>â€¢</dt>
<dd>For patients with <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, irregular cycles, or using a contraceptive method that precludes <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span>, perform the second pregnancy test immediately preceding the beginning of ABSORICA therapy and after the patient has used 2 forms of contraception for 1 month.</dd>
</dl>
<p>Each month of continued ABSORICA therapy, patients must have a negative result from a urine or serum pregnancy test. A pregnancy test must be repeated each month, in a CLIA-certified laboratory, prior to the female patient receiving each prescription. A pregnancy test must also be completed at the end of the entire course of isotretinoin therapy and 1 month after the discontinuation of isotretinoin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s83"></a><a name="section-8.5.2"></a><p></p>
<p class="First"><span class="Underline">Contraception</span></p>
<p>Females of childbearing potential must use 2 forms of effective contraception simultaneously, at least 1 of which must be a primary form, unless the patient commits to continuous abstinence from heterosexual contact, or the patient has undergone a hysterectomy or bilateral oophorectomy, or has been medically confirmed to be post-menopausal. Patients must use 2 forms of effective contraception for at least 1 month prior to initiation of ABSORICA therapy, during ABSORICA therapy, and for 1 month after discontinuing ABSORICA therapy. Micro-dosed progesterone preparations (â€œminipillsâ€? that do not contain an estrogen) are an inadequate method of contraception during isotretinoin therapy [<span class="Italics">seeWarnings and Precautions</span> (<a href="#s21">5.3</a>)].</p>
<p>Effective forms of contraception include both primary and secondary forms of contraception:</p>
<table width="100%">
<col width="63%">
<col width="37%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Primary forms</span></p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Secondary forms</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt>â€¢</dt>
<dd>Tubal sterilization</dd>
<dt>â€¢</dt>
<dd>Partnerâ€™s vasectomy</dd>
<dt>â€¢</dt>
<dd>Intrauterine device</dd>
<dt>â€¢</dt>
<dd>Hormonal (combination oral contraceptives, transdermal patch, injectables, implantables, or vaginal ring)</dd>
</dl></td>
<td class="Botrule Lrule Rrule">
<p class="First">Barrier:</p>
<dl>
<dt>â€¢</dt>
<dd>male latex condom with or without spermicide</dd>
<dt>â€¢</dt>
<dd>diaphragm with spermicide </dd>
<dt>â€¢</dt>
<dd>cervical cap with spermicide</dd>
</dl>
<p>Other:</p>
<dl>
<dt>â€¢</dt>
<dd>Vaginal sponge (contains spermicide)</dd>
</dl>
</td>
</tr>
</tbody>
</table>
<p>Any birth control method can fail. There have been reports of pregnancy from female patients who have used combination oral contraceptives, as well as transdermal patch/ injectable/ implantable/ vaginal ring hormonal birth control products; these pregnancies occurred while taking isotretinoin. These reports are more frequent for female patients who use only a single method of contraception. Therefore, it is critically important for female patients of childbearing potential use 2 effective forms of contraception simultaneously.</p>
<p>Using two forms of contraception simultaneously substantially reduces the chances that a female will become pregnant over the risk of pregnancy with either form alone. A drug interaction that decreases effectiveness of hormonal contraceptives has not been entirely ruled out for isotretinoin. Although hormonal contraceptives are highly effective, prescribers are advised to consult the package insert of any medication administered concomitantly with hormonal contraceptives, since some medications may decrease the effectiveness of these birth control products.</p>
<p>Patients should be prospectively cautioned not to self-medicate with the herbal supplement St. John's Wort because a possible interaction has been suggested with hormonal contraceptives based on reports of breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> on oral contraceptives shortly after starting St. John's Wort. Pregnancies have been reported by users of combined hormonal contraceptives who also used some form of St. John's Wort [<span class="Italics">see Drug Interactions</span> (<a href="#s70">7.4</a>)].</p>
<p>If the patient has unprotected heterosexual intercourse at any time 1 month before, during, or 1 month after therapy, she must:</p>
<dl>
<dt>â€¢</dt>
<dd>Stop taking ABSORICA immediately, if on therapy</dd>
<dt>â€¢</dt>
<dd>Have a pregnancy test at least 19 days after the last act of unprotected heterosexual intercourse</dd>
<dt>â€¢</dt>
<dd>Start using 2 forms of effective contraception simultaneously again for 1 month before resuming ABSORICA therapy</dd>
<dt>â€¢</dt>
<dd>Have a second pregnancy test after using 2 forms of effective contraception for 1 month as described above depending on whether she has regular menses or not.</dd>
</dl>
<p>If a pregnancy does occur during ABSORICA treatment, ABSORICA must be discontinued immediately. The patient should be referred to an Obstetrician-Gynecologist experienced in reproductive toxicity for further evaluation and counseling. Any suspected fetal exposure during or 1 month after ABSORICA therapy must be reported immediately to the FDA via the MedWatch number 1-800-FDA-1088 and also to the iPLEDGE pregnancy registry at 1-866-495-0654 or via the internet (<span class="Underline">www.ipledgeprogram.com</span>) [<span class="Italics">see Warnings and Precautions</span> (<a href="#s20">5.2</a>)].</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s84"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">In humans, overdosage has been associated with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span>, <span class="product-label-link" type="condition" conceptid="4039954" conceptname="Cheilosis">cheilosis</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>. These symptoms quickly resolve without apparent residual effects.</p>
<p>ABSORICA causes serious <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> at any dosage (see Boxed CONTRAINDICATIONS AND WARNINGS). Female patients of childbearing potential who present with ABSORICA <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> must be evaluated for pregnancy. Patients who are pregnant should receive counseling about the risks to the fetus, as described in the Boxed CONTRAINDICATIONS AND WARNINGS. Non-pregnant patients must be warned to avoid pregnancy for at least one month and receive contraceptive counseling as described in <span class="Italics">Warnings and Precautions (<a href="#s16">5</a>)</span>. Educational materials for such patients can be obtained by calling the manufacturer. Because an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> would be expected to result in higher levels of isotretinoin in semen than found during a normal treatment course, male patients should use a condom, or avoid reproductive sexual activity with a female patient who is or might become pregnant, for 1 month after the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. All patients with ABSORICA <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should not donate blood for at least 1 month.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s85"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">ABSORICA (isotretinoin) Capsules contain 10 mg, 20 mg, 25 mg, 30 mg, 35 mg or 40 mg of isotretinoin (a retinoid) in hard gelatin capsules for oral administration. In addition to the active ingredient, isotretinoin, each capsule contains the following inactive ingredients: propyl gallate, sorbitan monooleate, soybean oil and stearoyl polyoxylglycerides. The gelatin capsules contain the following dye systems: </p>
<dl>
<dt>â€¢</dt>
<dd>10 mg â€“ iron oxide (yellow) and titanium dioxide; </dd>
<dt>â€¢</dt>
<dd>20 mg â€“ iron oxide (red), and titanium dioxide; </dd>
<dt>â€¢</dt>
<dd>25 mg â€“ FD&amp;C Blue #1, FD&amp;C Yellow #5, FD&amp;C Yellow #6 and titanium dioxide; </dd>
<dt>â€¢</dt>
<dd>30 mg â€“ iron oxide (black, red and yellow) and titanium dioxide; </dd>
<dt>â€¢</dt>
<dd>35 mg â€“ FD&amp;C Blue #2, iron oxide (black, red and yellow) and titanium dioxide;</dd>
<dt>â€¢</dt>
<dd>40 mg â€“ iron oxide (black, red and yellow) and titanium dioxide.</dd>
</dl>
<p>Chemically, isotretinoin is 13-<span class="Italics">cis</span>-retinoic acid and is related to both retinoic acid and retinol (vitamin A). It is a yellow to orange crystalline powder with a molecular weight of 300.44. Â It is practically insoluble in water, soluble in chloroform and sparingly soluble in alcohol and in isopropyl alcohol. The structural formula is: </p>
<div class="Figure">
<a name="ID0EKQBI"></a><img alt="structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d54aab5-3349-4a41-8533-0a566fd7bbaa&amp;name=abs00-0001-01.jpg">
</div>
<p>Meets USP Dissolution Test 3.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s86"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s87"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">ABSORICA is a retinoid, which when administered in pharmacologic dosages of 0.5 to 1 mg/kg/day, inhibits sebaceous gland function and keratinization. Clinical improvement in nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients occurs in association with a reduction in sebum secretion. The decrease in sebum secretion is temporary and is related to the dose and duration of treatment with isotretinoin and reflects a reduction in sebaceous gland size and an inhibition of sebaceous gland differentiation. The exact mechanism of action of ABSORICA is unknown.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s88"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">The pharmacodynamics of ABSORICA are unknown.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s89"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s90"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Bold">Absorption</span></p>
<p>Due to its high lipophilicity, oral absorption of isotretinoin is enhanced when given with a high-fat meal. ABSORICA is bioequivalent to Accutane<span class="Sup">Â®</span> (isotretinoin) capsule when both drugs are taken with a high-fat meal. ABSORICA is more bioavailable than Accutane<span class="Sup">Â®</span> (isotretinoin) capsules when both drugs are taken fasted; the AUC<span class="Sub">0-t</span> of ABSORICA is approximately 83% greater than that of Accutane<span class="Sup">Â®.</span> ABSORICA is therefore not interchangeable with generic products of Accutane<span class="Sup">Â®</span>.</p>
<p>A single dose two-way crossover pharmacokinetic trial was conducted in 14 healthy adult male subjects comparing ABSORICA 40 mg (1 x 40 mg capsules), dosed under fasted and fed conditions. Under fed conditions after a high-fat meal, it was observed that the mean AUC<span class="Sub">0-t</span> and C<span class="Sub">max</span> were approximately 50% and 26% higher, than that observed under fasting conditions (<a href="#_Reft2">Table 2</a>). The observed elimination half-life (T<span class="Sub">1/2</span>) was slightly lower in the fed state versus fasted. The time to peak concentration (T<span class="Sub">max</span>) increased with food and this may be related to a longer absorption phase.</p>
<a name="_Reft2"></a><table width="100%">
<caption><span>Table 2: Pharmacokinetic parameters of ABSORICA mean (%CV) following administration of 40 mg strength, N=14</span></caption>
<col width="40%">
<col width="17%">
<col width="15%">
<col width="15%">
<col width="14%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center"><p class="First"><br>ABSORICAÂ¶ (1 x 40 mg capsules)</p></td>
<td class="Toprule" align="center"><p class="First"> AUC<span class="Sub">0-t</span><br>(ng x hr/mL)</p></td>
<td class="Toprule" align="center"><p class="First"> C<span class="Sub">max</span><br>(ng/mL)</p></td>
<td class="Toprule" align="center"><p class="First"> T<span class="Sub">max</span><br>(hr)</p></td>
<td class="Toprule" align="center"><p class="First"> T<span class="Sub">1/2</span><br>(hr)</p></td>
</tr>
<tr>
<td align="center"><p class="First"> Fed</p></td>
<td align="center"><p class="First"> 6095 (26 %)</p></td>
<td align="center"><p class="First"> 395 (39 %)</p></td>
<td align="center"><p class="First"> 6.4 (47 %)</p></td>
<td align="center"><p class="First"> 22 (25 %)</p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center"><p class="First"> Fasted</p></td>
<td class="Botrule" align="center"><p class="First"> 4055 (20 %)</p></td>
<td class="Botrule" align="center"><p class="First"> 314 (26 %)</p></td>
<td class="Botrule" align="center"><p class="First"> 2.9 (34 %)</p></td>
<td class="Botrule" align="center"><p class="First"> 24 (28 %)</p></td>
</tr>
</tbody>
</table>
<p>Published clinical literature has shown that there is no difference in the pharmacokinetics of isotretinoin between patients with nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> and healthy subjects with normal skin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s91"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Bold">Distribution</span></p>
<p>Isotretinoin is more than 99.9% bound to plasma proteins, primarily albumin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s92"></a><a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Bold">Metabolism</span></p>
<p>Following oral administration of isotretinoin, at least three metabolites have been identified in human plasma: 4-<span class="Italics">oxo</span>-isotretinoin, retinoic acid (tretinoin), and 4-<span class="Italics">oxo</span>-retinoic acid (4-<span class="Italics">oxo</span>-tretinoin). Retinoic acid and 13-cis-retinoic acid are geometric isomers and show reversible interconversion. The administration of one isomer will give rise to the other. Isotretinoin is also irreversibly oxidized to 4-<span class="Italics">oxo</span>-isotretinoin, which forms its geometric isomer 4-<span class="Italics">oxo</span>-tretinoin.</p>
<p>After a single 40 mg oral dose of ABSORICA to 57 healthy adult subjects, concurrent administration of food increased the extent of formation of all metabolites in plasma when compared to the extent of formation under fasted conditions.</p>
<p>All of these metabolites possess retinoid activity that is in some in vitro models more than that of the parent isotretinoin. However, the clinical significance of these models is unknown.</p>
<p>In vitro studies indicate that the primary P450 isoforms involved in isotretinoin metabolism are 2C8, 2C9, 3A4, and 2B6. Isotretinoin and its metabolites are further metabolized into conjugates, which are then excreted in urine and feces.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s93"></a><a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Bold">Elimination</span></p>
<p>Following oral administration of an 80 mg dose of 14C-isotretinoin as a liquid suspension, 14C-activity in blood declined with a half-life of 90 hours. The metabolites of isotretinoin and any conjugates are ultimately excreted in the feces and urine in relatively equal amounts (total of 65% to 83%).</p>
<p>After a single 40 mg (2 x 20 mg) oral dose of ABSORICA to 57 healthy adult subjects under fed conditions, the mean Â± SD elimination half-lives (T<span class="Sub">1/2</span>) of isotretinoin and 4-<span class="Italics">oxo</span>-isotretinoin under fed states were 18 hours and 38 hours, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s94"></a><a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Bold">Special Patient Populations</span></p>
<p>The pharmacokinetics of isotretinoin were evaluated after single and multiple doses in 38 pediatric patients (12 to 15 years) and 19 adult patients (â‰¥18 years) who received isotretinoin for the treatment of severe recalcitrant nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>. In both age groups, 4-<span class="Italics">oxo</span>-isotretinoin was the major metabolite; tretinoin and 4-<span class="Italics">oxo</span>-tretinoin were also observed. There were no statistically significant differences in the pharmacokinetics of isotretinoin between pediatric and adult patients.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s95"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s96"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis and Impairment of Fertility</h2>
<p class="First">In male and female Fischer 344 rats given oral isotretinoin at dosages of 8 or 32 mg/kg/day (1.3 to 5.3 times the recommended clinical dose of 1 mg/kg/day, respectively, after normalization for total body surface area) for greater than 18 months, there was a dose-related increased incidence of <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> relative to controls. The incidence of adrenal medullary <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> was also increased at the higher dosage in both sexes. The relatively high level of spontaneous <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytomas</span> occurring in the male Fischer 344 rat makes it an equivocal model for study of this tumor; therefore, the relevance of this tumor to the human population is uncertain.</p>
<p>The Ames test was conducted with isotretinoin in two laboratories. The results of the tests in one laboratory were negative while in the second laboratory a weakly positive response (less than 1.6 x background) was noted in <span class="Italics">S. typhimurium</span> TA100 when the assay was conducted with metabolic activation. No dose response effect was seen and all other <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> were negative. Additionally, other tests designed to assess genotoxicity (Chinese hamster cell assay, mouse micronucleus test, <span class="Italics">S. cerevisiae</span> D7 assay, in vitro clastogenesis assay with human-derived <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and unscheduled DNA synthesis assay) were all negative.</p>
<p>In rats, no adverse effects on gonadal function, fertility, conception rate, gestation or parturition were observed at oral dosages of isotretinoin of 2, 8, or 32 mg/kg/day (0.3, 1.3, or 5.3 times the recommended clinical dose of 1 mg/kg/day, respectively, after normalization for total body surface area).</p>
<p>In dogs, <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span> was noted after treatment with oral isotretinoin for approximately 30 weeks at dosages of 20 or 60 mg/kg/day (10 or 30 times the recommended clinical dose of 1 mg/kg/day, respectively, after normalization for total body surface area). In general, there was microscopic evidence for appreciable <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of spermatogenesis but some sperm were observed in all testes examined and in no instance were completely atrophic tubules seen.</p>
<p>In trials of 66 men, 30 of whom were patients with nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> under treatment with oral isotretinoin, no significant changes were noted in the count or motility of spermatozoa in the ejaculate. In a study of 50 men (ages 17 to 32 years) receiving isotretinoin therapy for nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, no significant effects were seen on ejaculate volume, sperm count, total sperm motility, morphology or seminal plasma fructose.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="s97"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology</h2>
<p class="First">In rats given 8 or 32 mg/kg/day of isotretinoin (1.3 to 5.3 times the recommended clinical dose of 1 mg/kg/day after normalization for total body surface area) for 18 months or longer, the incidences of focal calcification, <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the myocardium, calcification of coronary, pulmonary and mesenteric arteries, and metastatic calcification of the gastric mucosa were greater than in control rats of similar age. Focal endocardial and myocardial calcifications associated with calcification of the coronary arteries were observed in two dogs after approximately 6 to 7 months of treatment with isotretinoin at a dosage of 60 to 120 mg/kg/day (30 to 60 times the recommended clinical dose of 1 mg/kg/day, respectively, after normalization for total body surface area).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s98"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">A double-blind, randomized, parallel group trial (Study 1) was conducted in patients with severe recalcitrant nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> to evaluate the efficacy and safety of ABSORICA compared to a generic product of Accutane<span class="Sup">Â®</span> under fed conditions. Enrolled patients had a weight of 40 to 110 kg with at least 10 nodular lesions on the face and/or trunk. A total of 925 patients were randomized 1:1 to receive ABSORICA or a generic product of Accutane<span class="Sup">Â®</span> (isotretinoin). Study patients ranged from 12 to 54 years of age, were approximately 60% male, 40% female, and were 87% White, 4% Black, 6% Asian, and 3% Other. Patients were treated an initial dose of 0.5 mg/kg/day in two divided doses for the first 4 weeks followed by 1 mg/kg/day in two divided doses for the following 16 weeks.</p>
<p>Change from Baseline to Week 20 in total nodular lesion count and proportion of patients with at least a 90% reduction in total nodular lesion count from Baseline to Week 20 are presented in <a href="#_Reft3">Table 3</a>. Total nodular lesion counts by visit are presented in <a href="#_Ref">Figure 1</a>.</p>
<a name="_Reft3"></a><table width="100%">
<caption><span>Table 3: Efficacy Results at Week 20 (Study 1)</span></caption>
<col width="50%">
<col width="29%">
<col width="21%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="3" valign="top">*A generic product of Accutane<span class="Sup">Â®</span>
</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Toprule" align="center"><p class="First"><br>ABSORICAÂ¶<span class="Bold">N=464</span></p></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">Isotretinoin*</span><br><span class="Bold">N=461</span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Bold">Nodular Lesions</span><br>Mean Baseline Count<br>Mean Reduction</p></td>
<td align="center"><p class="First"><br>18.4<br>-15.68</p></td>
<td align="center"><p class="First"><br>17.7<br>-15.62</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"><span class="Bold">Patients Achieving 90% Reduction</span></p></td>
<td class="Botrule" align="center"><p class="First"> 324 (70%)</p></td>
<td class="Botrule" align="center"><p class="First"> 344 (75%)</p></td>
</tr>
</tbody>
</table>
<p>Figure 1: Total Nodular (Facial and Truncal) Lesion Count by Visit in Study 1</p>
<div class="Figure">
<a name="ID0EBBCI"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d54aab5-3349-4a41-8533-0a566fd7bbaa&amp;name=abs00-0001-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s99"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">ABSORICA (isotretinoin) Capsules are supplied  as follows:</p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">10 mg: </span>Dark yellow, opaque, capsule imprinted with black ink â€œ<span class="Bold">G 240</span>â€? on cap and â€œ<span class="Bold">10</span>â€? on the body </dd>
<dt>Â </dt>
<dd>Box of 30 capsules (3 x 10 Prescription Packs): NDC 10631-115-31</dd>
</dl>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">20 mg: </span>Red, opaque, capsule imprinted with black ink â€œ<span class="Bold">G 241</span>â€? on cap and â€œ<span class="Bold">20</span>â€? on the body </dd>
<dt>Â </dt>
<dd>Box of 30 capsules (3 x 10 Prescription Packs): NDC 10631-116-31</dd>
</dl>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">25 mg: </span>Green, opaque, capsule imprinted with white ink â€œ<span class="Bold">G 342</span>â€? on cap and â€œ<span class="Bold">25</span>â€? on the body</dd>
<dt>Â </dt>
<dd>Box of 30 capsules (3 x 10 Prescription Packs): NDC 10631-133-31</dd>
</dl>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">30 mg: </span>Brown, opaque, capsule imprinted with white ink â€œ<span class="Bold">G 242</span>â€? on cap and â€œ<span class="Bold">30</span>â€? on the body </dd>
<dt>Â </dt>
<dd>Box of 30 capsules (3 x 10 Prescription Packs): NDC 10631-117-31</dd>
</dl>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">35 mg:</span> Dark blue, opaque, capsule imprinted with white ink â€œ<span class="Bold">G 343</span>â€? on cap and â€œ<span class="Bold">35</span>â€? on the body</dd>
<dt>Â </dt>
<dd>Box of 30 capsules (3 x 10 Prescription Packs): NDC 10631-134-31</dd>
</dl>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">40 mg: </span>Brown and red, capsule imprinted with white ink â€œ<span class="Bold">G 325</span>â€? on cap and â€œ<span class="Bold">40</span>â€? on the body</dd>
<dt>Â </dt>
<dd>Box of 30 capsules (3 x 10 Prescription Packs): NDC10631-118-31</dd>
</dl>
<div class="Section" data-sectionCode="44425-7">
<a name="s100"></a><a name="section-14.1"></a><p></p>
<p class="First">Storage and Handling</p>
<p>Store at 20Â° C - 25Â° C (68Â° F - 77Â° F), excursion permitted between 15Â° C - 30Â° C (59Â° F - 86Â° F) [see USP controlled room temperature]. Protect from light.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s102"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="inv-59528dd9-b86b-4192-b66f-5f6f4a58ffd3"></a><a name="section-15.1"></a><p></p>
<p class="First">Advise the patient that ABSORICA is only available through a restricted program called iPLEDGE. </p>
<dl>
<dt>â€¢</dt>
<dd>As a component of the iPLEDGE program, prescribers must instruct patients to read the Medication Guide, the iPLEDGE program patient educational booklets, and watch the DVD with the following videos â€” â€œBe Prepared, Be Protectedâ€? and â€œBe Aware: The Risk of Pregnancy While on Isotretinoinâ€?. The DVD includes information about contraception, the most common reasons that contraception fails, and the importance of using 2 forms of effective contraception when taking teratogenic drugs and comprehensive information about types of potential <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> which could occur if a female patient who is pregnant takes ABSORICA at any time during pregnancy.</dd>
<dt>â€¢</dt>
<dd>Male patients and Female patients not of childbearing potential must understand the risks and benefits of ABSORICA, comply with the REMS requirements described in the booklet entitled <span class="Italics">The iPLEDGE Program Guide to Isotretinoin for Male Patients and Female Patients Who Cannot Get Pregnant</span>, and sign a Patient Information/Informed Consent form.</dd>
<dt>â€¢</dt>
<dd>Female patients of childbearing potential must be instructed that they must not be pregnant when ABSORICA therapy is initiated or plan to become pregnant while receiving ABSORICA therapy. Additionally, they must use 2 forms of effective contraception simultaneously for 1 month before starting ABSORICA, while taking ABSORICA, and for 1 month after ABSORICA has been stopped, unless they commit to continuous abstinence from heterosexual intercourse. They should also sign a Patient Information/Informed Consent form and Patient Information/Informed Consent About <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth Defects</span> (for female patients who can get pregnant) form prior to beginning ABSORICA therapy. Female patients should be seen by their prescribers monthly and have a urine or serum pregnancy test, in a CLIA-certified laboratory, performed each month during treatment to confirm negative pregnancy status before another ABSORICA prescription is written. Additionally, a pregnancy test must be completed at the end of the entire course of ABSORICA therapy and 1 month after discontinuation of therapy.</dd>
<dt>â€¢</dt>
<dd>Advise the patient that isotretinoin is found in the semen of male patients taking isotretinoin, but the amount delivered to a female partner would be about one million times lower than an oral dose of 40 mg.  While the no-effect limit for isotretinoin induced embryopathy is unknown, 20 years of post-marketing reports include four with isolated defects compatible with features of retinoid exposed fetuses; however two of these reports were incomplete and two had other possible explanations for the defects observed.</dd>
<dt>â€¢</dt>
<dd>Advise the patient that ABSORICA is available only from pharmacies that are certified in the iPLEDGE program, and provide them with the telephone number (1-866-495-0654) and website (<span class="Underline">www.ipledgeprogram.com</span>) for information on how to obtain.</dd>
<dt>â€¢</dt>
<dd>Advise patients that they may be requested to participate in a survey to evaluate the effectiveness of the iPLEDGE program.</dd>
<dt>â€¢</dt>
<dd>Prescribers should be alert to the warning signs of psychiatric disorders to guide patients to receive the help they need.  Therefore, prior to initiation of ABSORICA treatment, patients and family members should be asked about any history of psychiatric disorder, and at each visit during treatment patients should be assessed for symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, mood disturbance, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, or <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span> to determine if further evaluation may be necessary. Inform patients that <span class="Bold">symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> include sad mood, hopelessness, feelings of guilt, worthlessness or helplessness, loss of pleasure or interest in activities, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, difficulty concentrating, change in sleep pattern, change in weight or appetite, suicidal thoughts or attempts, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, acting on dangerous impulses, and persistent physical symptoms unresponsive to treatment</span>. Patients should stop treatment and the patient or a family member should promptly contact their prescriber if the patient develops <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, mood disturbance, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, or <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, without waiting until the next visit. Discontinuation of ABSORICA treatment may be insufficient; further evaluation may be necessary. While such monitoring may be helpful, it may not detect all patients at risk. Patients may report mental health problems or family history of psychiatric disorders. These reports should be discussed with the patient and/or the patient's family. A referral to a mental health professional may be necessary. The physician should consider whether ABSORICA therapy is appropriate in this setting; for some patients the risks may outweigh the benefits of ABSORICA therapy.</dd>
<dt>â€¢</dt>
<dd>Patients must be informed that some patients, while taking isotretinoin or soon after stopping isotretinoin, have become depressed or developed other serious mental problems. Symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> include sad, â€œanxiousâ€? or empty mood, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, acting on dangerous impulses, <span class="product-label-link" type="condition" conceptid="4327815" conceptname="Feeling angry">anger</span>, loss of pleasure or interest in social or sports activities, sleeping too much or too little, changes in weight or appetite, school or work performance going down, or trouble concentrating. Some patients taking isotretinoin have had thoughts about hurting themselves or putting an end to their own lives (suicidal thoughts), some have tried to end their own lives, and some have ended their own lives. There were reports that some of these people did not appear depressed. There have been reports of patients on isotretinoin becoming aggressive or violent. There have also been reports of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> symptoms, which indicate a loss of contact with reality. <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span> symptoms include feelings of suspiciousness toward others, strange beliefs, hearing voices or other noises without an obvious source, and seeing unusual objects or people with no explanation. No one knows if isotretinoin caused these behaviors and symptoms or if they would have happened even if the person did not take isotretinoin. If any of these behaviors or symptoms occur, the patient should stop treatment and the patient or family member should contact the prescriber promptly without waiting until the next visit [<span class="Italics">see Warnings and Precautions (5.4)</span>]. Some people have had other signs of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> while taking isotretinoin.</dd>
<dt>â€¢</dt>
<dd>Patients must be informed that they must not share ABSORICA with anyone else because of the risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and other serious adverse reactions.</dd>
<dt>â€¢</dt>
<dd>Patients must be informed not to donate blood during therapy and for 1 month following discontinuation of the drug because the blood might be given to a pregnant female patient whose fetus must not be exposed to ABSORICA.</dd>
<dt>â€¢</dt>
<dd>ABSORICA may be taken without regard to meals [<span class="Italics">see Dosage and Administration (2.1)</span>]. To decrease the risk of esophageal irritation, patients should swallow the capsules with a full glass of liquid.</dd>
<dt>â€¢</dt>
<dd>Patients should be informed that <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span> (including regional <span class="product-label-link" type="condition" conceptid="4203614" conceptname="Ileitis">ileitis</span>) may occur without a prior history of intestinal disorders. In rare instances, symptoms have been reported to persist after treatment has stopped. Patients should be informed that if they experience <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span> or severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, they should discontinue ABSORICA immediately.</dd>
<dt>â€¢</dt>
<dd>Patients should be informed that transient exacerbation (flare) of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> has been seen, generally during the initial period of therapy.</dd>
<dt>â€¢</dt>
<dd>Wax epilation and skin resurfacing procedures (such as dermabrasion, laser) should be avoided during ABSORICA therapy and for at least 6 months thereafter due to the possibility of <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scarring</span>.</dd>
<dt>â€¢</dt>
<dd>Patients should be advised to avoid prolonged exposure to UV rays or sunlight.</dd>
<dt>â€¢</dt>
<dd>Patients should be informed that they may experience <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>, corneal opacities, and <span class="product-label-link" type="condition" conceptid="374037" conceptname="Night blindness">decreased night vision</span>. Contact lens wearers may experience decreased tolerance to contact lenses during and after therapy.</dd>
<dt>â€¢</dt>
<dd>Patients should be informed that 16% of patients treated with isotretinoin in a clinical trial developed musculoskeletal symptoms (including <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>) during treatment. In general, these symptoms were mild to moderate, but occasionally required discontinuation of the drug. Transient <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the chest has been reported less frequently. In the clinical trial, these symptoms generally cleared rapidly after discontinuation of therapy, but in some cases persisted.</dd>
<dt>â€¢</dt>
<dd>There have been rare postmarketing reports of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, some associated with strenuous physical activity.</dd>
<dt>â€¢</dt>
<dd>Pediatric patients and their caregivers should be informed that approximately 17% to 29% of pediatric patients treated with isotretinoin developed <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>. In a clinical trial, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> was severe in 13.5% of the cases and occurred at a higher frequency in female patients than male patients. <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgias</span> were experienced in 22% (79/358) of pediatric patients. <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgias</span> were severe in 7.6% (6/79) of patients. Appropriate evaluation of the musculoskeletal system should be done in patients who present with these symptoms during or after a course of treatment. Consideration should be given to discontinuation of isotretinoin if any significant abnormality is found.</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> and rare cases of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported in patients treated with isotretinoin.  ABSORICA should be discontinued if clinically significant decreases in white cell counts occur.</dd>
<dt>â€¢</dt>
<dd>Patients should be advised that severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> (<span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>) have been reported in post marketing data in patients treated with isotretinoin. Treatment with ABSORICA should be discontinued if clinically significant <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> occur.</dd>
<dt>â€¢</dt>
<dd>Adolescent patients who participate in sports with repetitive impact should be informed that isotretinoin use may increase their risk of <span class="product-label-link" type="condition" conceptid="4167097" conceptname="Spondylolisthesis">spondylolisthesis</span> or hip growth plate injuries. There are spontaneous reports of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> and/or delayed healing in patients while on therapy with isotretinoin or following cessation of therapy with isotretinoin while involved in these activities [<span class="Italics">see Warnings and Precautions (5.12)</span>].</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="s103"></a><a name="section-16"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">ABSORICA<span class="Sup">Â®</span> (AB-SORE-I-KAH)</span><br><span class="Bold">(Isotretinoin Capsules)</span></p>
<p>Read the Medication Guide that comes with ABSORICA before you start taking it and each time you get a prescription. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.</p>
<p><span class="Bold">What is the most important information I should know about ABSORICA?</span></p>
<dl>
<dt>â€¢</dt>
<dd>ABSORICA is used to treat a type of severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> (nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>) that has not been helped by other treatments, including antibiotics.</dd>
<dt>â€¢</dt>
<dd>Because ABSORICA can cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>, ABSORICA is only for patients who can understand and agree to carry out all of the instructions in the iPLEDGE program.</dd>
<dt>â€¢</dt>
<dd>ABSORICA may cause serious mental health problems. </dd>
</dl>
<p>1.<span class="Bold">	<span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth defects</span> (deformed babies), loss of a baby before birth (<span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span>), <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of the baby, and early (premature) births.</span>	 Female patients who are pregnant or who plan to become pregnant must not take ABSORICA. <span class="Bold">	Female patients must not get pregnant:</span></p>
<dl>
<dt>â€¢</dt>
<dd>for 1 month before starting ABSORICA</dd>
<dt>â€¢</dt>
<dd>while taking ABSORICA</dd>
<dt>â€¢</dt>
<dd>for 1 month after stopping ABSORICA.</dd>
</dl>
<p><span class="Bold">Ifyou get pregnant while taking ABSORICA, stop taking it right away and call your doctor.</span> Doctors and patients should report all cases of pregnancy to:</p>
<dl>
<dt>â€¢</dt>
<dd>FDA MedWatch at 1-800-FDA-1088, and</dd>
<dt>â€¢</dt>
<dd>the iPLEDGE pregnancy registry at 1-866-495-0654</dd>
</dl>
<p><span class="Bold">2.	Serious mental health problems.</span> ABSORICA may cause:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></span></dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span></span> (seeing or hearing things that are not real) </dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span></span>. Some patients taking ABSORICA have had thoughts about hurting themselves or putting an end to their own lives (suicidal thoughts). Some people tried to end their own lives. And some people have ended their own lives.</dd>
</dl>
<p><span class="Bold">Stop ABSORICA and call your doctor right away if you or a family member notices that you have any of the following signs and symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>:</span></p>
<dl>
<dt>â€¢</dt>
<dd>start to feel sad or have <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span> spells</dd>
<dt>â€¢</dt>
<dd>lose interest in activities you once enjoyed</dd>
<dt>â€¢</dt>
<dd>sleep too much or have trouble sleeping</dd>
<dt>â€¢</dt>
<dd>become more <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritable</span>, angry, or aggressive than usual (for example, temper outbursts, thoughts of violence)</dd>
<dt>â€¢</dt>
<dd>have a change in your appetite or body weight</dd>
<dt>â€¢</dt>
<dd>have trouble concentrating</dd>
<dt>â€¢</dt>
<dd>withdraw from your friends or family</dd>
<dt>â€¢</dt>
<dd>feel like you have no energy</dd>
<dt>â€¢</dt>
<dd>have feelings of worthlessness or guilt</dd>
<dt>â€¢</dt>
<dd>start having thoughts about hurting yourself or taking your own life (suicidal thoughts)</dd>
<dt>â€¢</dt>
<dd>start acting on dangerous impulses </dd>
<dt>â€¢</dt>
<dd>start seeing or hearing things that are not real</dd>
</dl>
<p>After stopping ABSORICA, you may also need follow-up mental health care if you had any of these symptoms.</p>
<p><span class="Bold">What is ABSORICA?</span></p>
<p>ABSORICA is a medicine taken by mouth to treat the most severe form of <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> (nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>) that cannot be cleared up by any other <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> treatments, including antibiotics. ABSORICA can cause serious side effects (see <span class="Bold">â€œ<a href="#_Ref">What is the most important information I should know about ABSORICA?</a>â€?</span>). ABSORICA can only be:</p>
<dl>
<dt>â€¢</dt>
<dd>prescribed by doctors that are registered in the iPLEDGE program</dd>
<dt>â€¢</dt>
<dd>dispensed by a pharmacy that is registered with the iPLEDGE program</dd>
<dt>â€¢</dt>
<dd>given to patients who are registered in the iPLEDGE program and agree to do everything required in the program</dd>
</dl>
<p><span class="Bold">What is severe nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>?</span></p>
<p>Severe nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> is when many red, swollen, tender lumps form in the skin. These can be the size of pencil erasers or larger. If untreated, nodular <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> can lead to permanent <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scars</span>.</p>
<p><span class="Bold">Who should not take ABSORICA?</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Do not take ABSORICA if you are pregnant, plan to become pregnant, or become pregnant during ABSORICA treatment.</span> ABSORICA causes severe <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. See <span class="Bold">â€œ<a href="#_Ref">What is the most important information I should know about ABSORICA?</a>â€?</span>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Do not take ABSORICA if you are allergic to anything in it.</span> See the end of this Medication Guide for a complete list of ingredients in ABSORICA.</dd>
</dl>
<p><span class="Bold">What should I tell my doctor before taking ABSORICA?</span></p>
<p><span class="Bold">Tell your doctor if you or a family member has any of the following health conditions:</span></p>
<dl>
<dt>â€¢</dt>
<dd>mental problems</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></dd>
<dt>â€¢</dt>
<dd>liver disease</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></dd>
<dt>â€¢</dt>
<dd>heart disease</dd>
<dt>â€¢</dt>
<dd>bone loss (<span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>) or weak bones</dd>
<dt>â€¢</dt>
<dd>an eating problem called <span class="product-label-link" type="condition" conceptid="436675" conceptname="Anorexia nervosa">anorexia nervosa</span> (where people eat too little)</dd>
<dt>â€¢</dt>
<dd>food or medicine allergies</dd>
</dl>
<p><span class="Bold">Tell your doctor if you are pregnant or breast-feeding. ABSORICA must not be used by women who are pregnant or breast-feeding.</span></p>
<p><span class="Bold">Tell your doctor about all of the medicines you take including prescription and non-prescription medicines, vitamins and herbal supplements.</span> ABSORICA and certain other medicines can interact with each other, sometimes causing serious side effects. Especially tell your doctor if you take:</p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Vitamin A supplements</span>. Vitamin A in high doses has many of the same side effects as ABSORICA. Taking both together may increase your chance of getting side effects.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Tetracycline antibiotics</span>. Tetracycline antibiotics taken with ABSORICA can increase the chances of getting increased pressure in the brain.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Progestin-only birth control pills (mini-pills)</span>. They may not work while you take ABSORICA. Ask your doctor or pharmacist if you are not sure what type you are using.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Dilantin (phenytoin)</span>. This medicine taken with ABSORICA may weaken your bones.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Corticosteroid medicines</span>. These medicines taken with ABSORICA may weaken your bones.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">St. John's Wort</span>. This herbal supplement may make birth control pills work less effectively.</dd>
</dl>
<p><span class="Bold">These medicines should not be used with ABSORICA unless your doctor tells you it is okay.</span></p>
<p>Know the medicines you take. Keep a list of them to show to your doctor and pharmacist. Do not take any new medicine without talking with your doctor.</p>
<p><span class="Bold">How should I take ABSORICA?</span></p>
<dl>
<dt>â€¢</dt>
<dd>You must take ABSORICA exactly as prescribed. You must also follow all the instructions of the iPLEDGE program. Before prescribing ABSORICA, your doctor will:<dl>
<dt>â€¢</dt>
<dd>explain the iPLEDGE program to you</dd>
<dt>â€¢</dt>
<dd>have you sign the Patient Information/Informed Consent form (for all patients). Female patients who can get pregnant must also sign another consent form.</dd>
</dl>
</dd>
</dl>
<p><span class="Bold">You will not be prescribed ABSORICA if you cannot agree to or follow all the instructions of the iPLEDGE program.</span></p>
<dl>
<dt>â€¢</dt>
<dd>You will get no more than a 30-day supply of ABSORICA at a time. This is to make sure you are following the ABSORICA iPLEDGE program. You should talk with your doctor each month about side effects.</dd>
<dt>â€¢</dt>
<dd>The amount of ABSORICA you take has been specially chosen for you. It is based on your body weight, and may change during treatment.</dd>
<dt>â€¢</dt>
<dd>Take ABSORICA 2 times a day without regard to meals, unless your doctor tells you otherwise. <span class="Bold">Swallow your ABSORICA capsules whole with a full glass of liquid. Do not chew or suck on the capsule.</span> ABSORICA can hurt the tube that connects your mouth to your stomach (esophagus) if it is not swallowed whole.</dd>
<dt>â€¢</dt>
<dd>If you miss a dose, just skip that dose. Do <span class="Bold">not</span> take two doses at the same time.</dd>
<dt>â€¢</dt>
<dd>If you take too much ABSORICA or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, call your doctor or poison control center right away.</dd>
<dt>â€¢</dt>
<dd>Your <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> may get worse when you first start taking ABSORICA. This should last only a short while. Talk with your doctor if this is a problem for you.</dd>
<dt>â€¢</dt>
<dd>You must return to your doctor as directed to make sure you don't have signs of serious side effects. Your doctor may do blood tests to check for serious side effects from ABSORICA. Female patients who can get pregnant will get a pregnancy test each month.</dd>
<dt>â€¢</dt>
<dd>Female patients who can get pregnant must agree to use two separate forms of effective birth control at the same time one month before, while taking, and for one month after taking ABSORICA. <span class="Bold">You must access the iPLEDGE system to answer questions about the program requirements and to enter your two chosen forms of birth control.</span> To access the iPLEDGE system, go to <span class="Italics">www.ipledgeprogram.com</span>  or call 1-866-495-0654.<br><br>You must talk about effective birth control methods with your doctor or go for a free visit to talk about birth control with another doctor or family planning expert. Your doctor can arrange this <span class="Underline">free</span> visit, which will be paid for by the company that makes ABSORICA.<br><br><span class="Bold">If you have sex at any time without using two forms of effective birth control, get pregnant, or miss your expected period, stop using ABSORICA and call your doctor right away.</span>
</dd>
</dl>
<p><span class="Bold">What should I avoid while taking ABSORICA?</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">Do not get pregnant</span> while taking ABSORICA and for one month after stopping ABSORICA. See <span class="Bold">â€œ<a href="#_Ref">What is the most important information I should know about ABSORICA?</a>â€?</span>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Do not breast-feed</span> while taking ABSORICA and for one month after stopping ABSORICA. We do not know if ABSORICA can pass through your milk and harm the baby.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Do not give blood</span> while you take ABSORICA and for one month after stopping ABSORICA. If someone who is pregnant gets your donated blood, her baby may be exposed to ABSORICA and may be born with <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Do not take other medicines or herbal products</span> with ABSORICA unless you talk to your doctor. See <span class="Bold">â€œ<a href="#_Ref">What should I tell my doctor before taking ABSORICA?</a>â€?</span>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Do not drive at night until you know if ABSORICA has affected your vision.</span> ABSORICA may decrease your ability to see in the dark.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Do not have cosmetic procedures to smooth your skin, including waxing, dermabrasion, or laser procedures, while you are using ABSORICA and for at least 6 months after you stop.</span> ABSORICA can increase your chance of <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scarring</span> from these procedures. Check with your doctor for advice about when you can have cosmetic procedures.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Avoid sunlight and ultraviolet lights</span> as much as possible. Tanning machines use ultraviolet lights. ABSORICA may make your skin more sensitive to light.</dd>
</dl>
<p><span class="Bold">Do not share ABSORICA with other people.</span> It can cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and other serious health problems.</p>
<p><span class="Bold">What are the possible side effects of ABSORICA?</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">ABSORICA can cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> (deformed babies), loss of a baby before birth (<span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span>), <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of the baby, and early (premature) births. See â€œ<a href="#_Ref">What is the most important information I should know about ABSORICA?</a>â€?</span></dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">ABSORICA may cause serious mental health problems.</span> See <span class="Bold">â€œ<a href="#_Ref">What is the most important information I should know about ABSORICA?</a>â€?</span>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">serious brain problems.</span> ABSORICA can increase the pressure in your brain. This can lead to permanent loss of eyesight and, in rare cases, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Stop taking ABSORICA and call your doctor right away if you get any of these signs of increased brain pressure:<dl>
<dt>â€¢</dt>
<dd>bad <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">skin problems.</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> can occur in patients taking ABSORICA. In some patients a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> can be serious. Stop using ABSORICA and call your doctor right away if you develop <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> (red or inflamed eyes, like â€œpink eyeâ€?), a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> with a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> on legs, arms or face and/or sores in your mouth, throat, nose, eyes, or if your skin begins to peel.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">stomach area (abdomen) problems.</span> Certain symptoms may mean that your internal organs are being damaged. These organs include the liver, pancreas, bowel (intestines), and esophagus (connection between mouth and stomach). If your organs are damaged, they may not get better even after you stop taking ABSORICA. Stop taking ABSORICA and call your doctor if you get:<dl>
<dt>â€¢</dt>
<dd>severe stomach, chest or bowel <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></dd>
<dt>â€¢</dt>
<dd>trouble swallowing or painful swallowing</dd>
<dt>â€¢</dt>
<dd>new or worsening <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span></dd>
<dt>â€¢</dt>
<dd>yellowing of your skin or eyes</dd>
<dt>â€¢</dt>
<dd>dark urine</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">bone and muscle problems.</span> ABSORICA may affect bones, muscles, and ligaments and cause <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your joints or muscles. Tell your doctor if you plan hard physical activity during treatment with ABSORICA. Tell your doctor if you get:<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span></dd>
<dt>â€¢</dt>
<dd>broken bone. Tell all healthcare providers that you take ABSORICA if you break a bone.<br><br><span class="Bold">Stop ABSORICA and call your doctor right away if you have <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>. <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span> with or without <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> can be a sign of serious <span class="product-label-link" type="condition" conceptid="4048093" conceptname="Hamstring injury">muscle damage</span>.</span><br><br>ABSORICA may stop long bone growth in teenagers who are still growing.</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">hearing problems.</span> Stop using ABSORICA and call your doctor if your hearing gets worse or if you have ringing in your ears. Your <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> may be permanent.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">vision problems.</span> ABSORICA may affect your ability to see in the dark. This condition usually clears up after you stop taking ABSORICA, but it may be permanent. Other serious eye effects can occur. Stop taking ABSORICA and call your doctor right away if you have any problems with your vision or dryness of the eyes that is painful or constant. If you wear contact lenses, you may have trouble wearing them while taking ABSORICA and after treatment.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">lipid (fats and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in blood) problems.</span> ABSORICA can raise the level of fats and <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in your blood. This can be a serious problem. Return to your doctor for blood tests to check your lipids and to get any needed treatment. These problems usually go away when ABSORICA treatment is finished.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</span> Stop taking ABSORICA and get emergency care right away if you develop <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, a swollen face or mouth, or have trouble breathing. Stop taking ABSORICA and call your doctor if you get a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, or red patches or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruises</span> on your legs.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">blood sugar problems.</span> ABSORICA may cause blood sugar problems including <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Tell your doctor if you are very thirsty or urinate a lot.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">decreased red and white blood cells.</span> Call your doctor if you have trouble breathing, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, or feel weak.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">The common, less serious side effects of ABSORICA</span> are <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="4039954" conceptname="Cheilosis">chapped lips</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>, and <span class="product-label-link" type="condition" conceptid="4171214" conceptname="Nasal mucosa dry">dry nose</span> that may lead to <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">nosebleeds</span>. Call your doctor if you get any side effect that bothers you or that does not go away.</dd>
</dl>
<p>These are not all of the possible side effects with ABSORICA. Your doctor or pharmacist can give you more detailed information.</p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span></p>
<p><span class="Bold">You may also report side effects to Ranbaxy Inc., the manufacturer of ABSORICA at 1-800-406-7984.</span></p>
<p><span class="Bold">How should I store ABSORICA?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Store ABSORICA at room temperature, 68Â° to 77Â° F (20Â° to 25Â° C). Protect from light.</dd>
<dt>â€¢</dt>
<dd><span class="Bold">Keep ABSORICA and all medicines out of the reach of children.</span></dd>
</dl>
<p><span class="Bold">General Information about ABSORICA</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in Medication Guides. Do not use ABSORICA for a condition for which it was not prescribed. Do not give ABSORICA to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about ABSORICA. If you would like more information, talk with your doctor.</p>
<p>You can ask your doctor or pharmacist for information about ABSORICA that is written for health care professionals. You can also call iPLEDGE program at 1-866-495-0654 or visit <span class="Underline">www.ipledgeprogram.com</span>.</p>
<p><span class="Bold">What are the ingredients in ABSORICA?</span></p>
<p><span class="Bold">Active ingredient:</span> Isotretinoin, USP</p>
<p><span class="Bold">Inactive ingredients:</span> Propyl gallate, sorbitan monooleate, soybean oil and stearoyl polyoxylglycerides. Gelatin capsules contain the following dye systems: 10 mg â€“ iron oxide (yellow), potassium hydroxide, propylene glycol, shellac and titanium dioxide; 20 mg â€“ iron oxide (red), potassium hydroxide, propylene glycol, shellac and titanium dioxide; 25 mg â€“ FD&amp;C Blue #1, FD&amp;C Yellow #5, FD&amp;C Yellow #6, povidone, propylene glycol, shellac, sodium hydroxide and titanium dioxide; 30 mg â€“ iron oxide (black, red and yellow), potassium hydroxide, povidone, propylene glycol, shellac, sodium hydroxide and titanium dioxide; 35 mg â€“ FD&amp;C Blue #2, iron oxide (black, red and yellow), povidone, propylene glycol, shellac, sodium hydroxide and titanium dioxide; and 40 mg â€“ iron oxide (black, red and yellow), potassium hydroxide, povidone, propylene glycol, shellac, sodium hydroxide and titanium dioxide.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Dilantin is a registered trademark of Warner-Lambert Company LLC.</p>
<p>Distributed By:</p>
<p><span class="Bold">Ranbaxy Laboratories Inc.</span><br>Ranbaxy Laboratories Inc.<br>Jacksonville, FL 32257 USA</p>
<p>GK-244 	Revised: xx 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_6160df32-050b-483a-8199-a8f13bd47f6e"></a><a name="section-17"></a><p></p>
<h1>Package/Label Display Panel</h1>
<p class="First"><span class="Bold">Attention Pharmacist: Dispense with enclosed Medication Guide.</span></p>
<p>NDC 10631-115-69</p>
<p><span class="Bold">Absorica<span class="Sup">Â®</span> (isotretinoin) Capsules</span></p>
<p><span class="Bold">10 mg</span></p>
<p>Each capsule contains 10 mg Isotretinoin, USP</p>
<p><span class="Bold">10 Capsules</span></p>
<p><span class="Bold">Prescription Pack</span></p>
<p><span class="Bold">PATIENT: READ INFORMATION CAREFULLY</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure">
<a name="id-1542225226"></a><img alt="F:\US-SUBMISSIONS\Labeling Database\US\Absorica (Isotretinoin Capsules) 10,20,30,40 mg - NDA 021951\Post-Approval\Supplements\FDA Contact 23-Jul-2014\Working Files\prev sub spl\label-001.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d54aab5-3349-4a41-8533-0a566fd7bbaa&amp;name=image-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_584029e3-b2a5-44b8-ade9-00314016f1ea"></a><a name="section-18"></a><p></p>
<h1>Package/Label Display Panel</h1>
<p class="First"><span class="Bold">NDC 10631-115-31</span></p>
<p><span class="Bold">Absorica<span class="Sup">Â®</span> (isotretinoin) Capsules</span></p>
<p><span class="Bold">10 mg</span></p>
<p>Each capsule contains 10 mg Isotretinoin, USP </p>
<p><span class="Bold">30 Capsules</span> (3 x 10 Prescription Packs)</p>
<p><span class="Bold">Attention Pharmacist: Dispense with enclosed Medication Guide.</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">CAUSES <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">BIRTH DEFECTS</span></span></p>
<p><span class="Bold">DO NOT GET PREGNANT</span></p>
<div class="Figure">
<a name="id-1542223391"></a><img alt="10 mg Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d54aab5-3349-4a41-8533-0a566fd7bbaa&amp;name=image-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_e9b77aee-0ec2-4185-b5d5-364031d4531d"></a><a name="section-19"></a><p></p>
<h1>Package/Label Display Panel</h1>
<p class="First"><span class="Bold">Attention Pharmacist: Dispense with enclosed Medication Guide.</span></p>
<p>NDC 10631-116-69</p>
<p><span class="Bold">Absorica<span class="Sup">Â®</span> (isotretinoin) Capsules</span></p>
<p><span class="Bold">20 mg</span></p>
<p>Each capsule contains 20 mg Isotretinoin, USP</p>
<p><span class="Bold">10 Capsules</span></p>
<p><span class="Bold">Prescription Pack</span></p>
<p><span class="Bold">PATIENT: READ INFORMATION CAREFULLY</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure">
<a name="id-1542221529"></a><img alt="20 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Card" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d54aab5-3349-4a41-8533-0a566fd7bbaa&amp;name=image-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_d43255ca-f4f8-4db2-ac02-a2db622e225a"></a><a name="section-20"></a><p></p>
<h1>Package/Label Display Panel</h1>
<p class="First"><span class="Bold">NDC 10631-116-31</span></p>
<p><span class="Bold">Absorica<span class="Sup">Â®</span> (isotretinoin) Capsules</span></p>
<p><span class="Bold">20 mg</span></p>
<p>Each capsule contains 20 mg Isotretinoin, USP </p>
<p><span class="Bold">30 Capsules</span> (3 x 10 Prescription Packs)</p>
<p><span class="Bold">Attention Pharmacist: Dispense with enclosed Medication Guide.</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">CAUSES <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">BIRTH DEFECTS</span></span></p>
<p><span class="Bold">DO NOT GET PREGNANT</span></p>
<div class="Figure">
<a name="id-1542220042"></a><img alt="20 mg Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d54aab5-3349-4a41-8533-0a566fd7bbaa&amp;name=image-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_2027196e-3c92-4e7b-9d48-5a33b72c0bf5"></a><a name="section-21"></a><p></p>
<h1>Package/Label Display Panel</h1>
<p class="First"><span class="Bold">Attention Pharmacist: Dispense with enclosed Medication Guide.</span></p>
<p>NDC 10631-133-69</p>
<p><span class="Bold">Absorica<span class="Sup">Â®</span> (isotretinoin) Capsules</span></p>
<p><span class="Bold">25 mg</span></p>
<p>Each capsule contains 25 mg Isotretinoin, USP</p>
<p><span class="Bold">10 Capsules</span></p>
<p><span class="Bold">Prescription Pack</span></p>
<p><span class="Bold">PATIENT: READ INFORMATION CAREFULLY</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure">
<a name="id-1542218141"></a><img alt="25 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Card" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d54aab5-3349-4a41-8533-0a566fd7bbaa&amp;name=image-05.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_8e886810-cf97-4fb7-9b77-a8a2c7554ae0"></a><a name="section-22"></a><p></p>
<h1>Package/Label Display Panel</h1>
<p class="First"><span class="Bold">NDC 10631-133-31</span></p>
<p><span class="Bold">Absorica<span class="Sup">Â®</span> (isotretinoin) Capsules</span></p>
<p><span class="Bold">25 mg</span></p>
<p>Each capsule contains 25 mg Isotretinoin, USP </p>
<p><span class="Bold">30 Capsules</span> (3 x 10 Prescription Packs)</p>
<p><span class="Bold">Attention Pharmacist: Dispense with enclosed Medication Guide.</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">CAUSES <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">BIRTH DEFECTS</span></span></p>
<p><span class="Bold">DO NOT GET PREGNANT</span></p>
<div class="Figure">
<a name="id-1542216179"></a><img alt="25 mg Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d54aab5-3349-4a41-8533-0a566fd7bbaa&amp;name=image-06.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_d43bc210-8ab7-4653-9ca3-9045180cb750"></a><a name="section-23"></a><p></p>
<h1>Package/Label Display Panel</h1>
<p class="First"><span class="Bold">Attention Pharmacist: Dispense with enclosed Medication Guide.</span></p>
<p>NDC 10631-117-69</p>
<p><span class="Bold">Absorica<span class="Sup">Â®</span> (isotretinoin) Capsules</span></p>
<p><span class="Bold">30 mg</span></p>
<p>Each capsule contains 30 mg Isotretinoin, USP</p>
<p><span class="Bold">10 Capsules</span></p>
<p><span class="Bold">Prescription Pack</span></p>
<p><span class="Bold">PATIENT: READ INFORMATION CAREFULLY</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure">
<a name="id-1542214613"></a><img alt="30 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> card" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d54aab5-3349-4a41-8533-0a566fd7bbaa&amp;name=image-07.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_178f5dc5-e829-436b-b3cc-aef3ec7a9cee"></a><a name="section-24"></a><p></p>
<h1>Package/Label Display Panel</h1>
<p class="First"><span class="Bold">NDC 10631-117-31</span></p>
<p><span class="Bold">Absorica<span class="Sup">Â®</span> (isotretinoin) Capsules</span></p>
<p><span class="Bold">30 mg</span></p>
<p>Each capsule contains 30 mg Isotretinoin, USP </p>
<p><span class="Bold">30 Capsules</span> (3 x 10 Prescription Packs)</p>
<p><span class="Bold">Attention Pharmacist: Dispense with enclosed Medication Guide.</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">CAUSES <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">BIRTH DEFECTS</span></span></p>
<p><span class="Bold">DO NOT GET PREGNANT</span></p>
<div class="Figure">
<a name="id-1542212655"></a><img alt="30 mg Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d54aab5-3349-4a41-8533-0a566fd7bbaa&amp;name=image-08.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_060f101d-15d5-4a84-b5d5-9cb9bc07ec21"></a><a name="section-25"></a><p></p>
<h1>Package/Label Display Panel</h1>
<p class="First"><span class="Bold">Attention Pharmacist: Dispense with enclosed Medication Guide.</span></p>
<p>NDC 10631-134-69</p>
<p><span class="Bold">Absorica<span class="Sup">Â®</span> (isotretinoin) Capsules</span></p>
<p><span class="Bold">35 mg</span></p>
<p>Each capsule contains 35 mg Isotretinoin, USP</p>
<p><span class="Bold">10 Capsules</span></p>
<p><span class="Bold">Prescription Pack</span></p>
<p><span class="Bold">PATIENT: READ INFORMATION CAREFULLY</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure">
<a name="id-1542210673"></a><img alt="35 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Card" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d54aab5-3349-4a41-8533-0a566fd7bbaa&amp;name=image-09.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_a35b934d-5636-450f-8596-002bec4594c9"></a><a name="section-26"></a><p></p>
<h1>Package/Label Display Panel</h1>
<p class="First"><span class="Bold">NDC 10631-134-31</span></p>
<p><span class="Bold">Absorica<span class="Sup">Â®</span> (isotretinoin) Capsules</span></p>
<p><span class="Bold">35 mg</span></p>
<p>Each capsule contains 35 mg Isotretinoin, USP </p>
<p><span class="Bold">30 Capsules</span> (3 x 10 Prescription Packs)</p>
<p><span class="Bold">Attention Pharmacist: Dispense with enclosed Medication Guide.</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">CAUSES <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">BIRTH DEFECTS</span></span></p>
<p><span class="Bold">DO NOT GET PREGNANT</span></p>
<div class="Figure">
<a name="id-1542208713"></a><img alt="35 mg Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d54aab5-3349-4a41-8533-0a566fd7bbaa&amp;name=image-10.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_aba5dc18-caf5-4cda-9974-d709d01bd6b6"></a><a name="section-27"></a><p></p>
<h1>Package/Label Display Panel</h1>
<p class="First"><span class="Bold">Attention Pharmacist: Dispense with enclosed Medication Guide.</span></p>
<p>NDC 10631-118-69</p>
<p><span class="Bold">Absorica<span class="Sup">Â®</span> (isotretinoin) Capsules</span></p>
<p><span class="Bold">40 mg</span></p>
<p>Each capsule contains 40 mg Isotretinoin, USP</p>
<p><span class="Bold">10 Capsules</span></p>
<p><span class="Bold">Prescription Pack</span></p>
<p><span class="Bold">PATIENT: READ INFORMATION CAREFULLY</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure">
<a name="id-1542206733"></a><img alt="40 mg <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Card" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d54aab5-3349-4a41-8533-0a566fd7bbaa&amp;name=image-11.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_2aae957b-620a-499a-a8b0-f84d53c95f42"></a><a name="section-28"></a><p></p>
<h1>Package/Label Display Panel</h1>
<p class="First"><span class="Bold">NDC 10631-118-31</span></p>
<p><span class="Bold">Absorica<span class="Sup">Â®</span> (isotretinoin) Capsules</span></p>
<p><span class="Bold">40 mg</span></p>
<p>Each capsule contains 40 mg Isotretinoin, USP </p>
<p><span class="Bold">30 Capsules</span> (3 x 10 Prescription Packs)</p>
<p><span class="Bold">Attention Pharmacist: Dispense with enclosed Medication Guide.</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">CAUSES <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">BIRTH DEFECTS</span></span></p>
<p><span class="Bold">DO NOT GET PREGNANT</span></p>
<div class="Figure">
<a name="id-1542204733"></a><img alt="40 mg Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8d54aab5-3349-4a41-8533-0a566fd7bbaa&amp;name=image-12.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ABSORICAÂ 		
					</strong><br><span class="contentTableReg">isotretinoin capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10631-115</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ISOTRETINOIN</strong> (ISOTRETINOIN) </td>
<td class="formItem">ISOTRETINOIN</td>
<td class="formItem">10Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SOYBEAN OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITAN MONOOLEATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYL GALLATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PEG-32 HYDROGENATED PALM GLYCERIDES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">G;240</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10631-115-31</td>
<td class="formItem">3  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10631-115-69</td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021951</td>
<td class="formItem">06/08/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ABSORICAÂ 		
					</strong><br><span class="contentTableReg">isotretinoin capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10631-116</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ISOTRETINOIN</strong> (ISOTRETINOIN) </td>
<td class="formItem">ISOTRETINOIN</td>
<td class="formItem">20Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SOYBEAN OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITAN MONOOLEATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYL GALLATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PEG-32 HYDROGENATED PALM GLYCERIDES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (red) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">G;241</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10631-116-31</td>
<td class="formItem">3  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10631-116-69</td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021951</td>
<td class="formItem">06/08/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ABSORICAÂ 		
					</strong><br><span class="contentTableReg">isotretinoin capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10631-117</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ISOTRETINOIN</strong> (ISOTRETINOIN) </td>
<td class="formItem">ISOTRETINOIN</td>
<td class="formItem">30Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SOYBEAN OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITAN MONOOLEATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYL GALLATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PEG-32 HYDROGENATED PALM GLYCERIDES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (brown) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">23mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">G;242</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10631-117-31</td>
<td class="formItem">3  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10631-117-69</td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021951</td>
<td class="formItem">06/08/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ABSORICAÂ 		
					</strong><br><span class="contentTableReg">isotretinoin capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10631-118</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ISOTRETINOIN</strong> (ISOTRETINOIN) </td>
<td class="formItem">ISOTRETINOIN</td>
<td class="formItem">40Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SOYBEAN OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITAN MONOOLEATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYL GALLATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PEG-32 HYDROGENATED PALM GLYCERIDES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (brown, red) ,Â RED</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">25mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">G;325</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10631-118-31</td>
<td class="formItem">3  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10631-118-69</td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021951</td>
<td class="formItem">06/08/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ABSORICAÂ 		
					</strong><br><span class="contentTableReg">isotretinoin capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10631-133</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ISOTRETINOIN</strong> (ISOTRETINOIN) </td>
<td class="formItem">ISOTRETINOIN</td>
<td class="formItem">25Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SOYBEAN OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITAN MONOOLEATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYL GALLATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 5</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PEG-32 HYDROGENATED PALM GLYCERIDES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN (green) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">G;342</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10631-133-31</td>
<td class="formItem">3  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10631-133-69</td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021951</td>
<td class="formItem">06/08/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ABSORICAÂ 		
					</strong><br><span class="contentTableReg">isotretinoin capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10631-134</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ISOTRETINOIN</strong> (ISOTRETINOIN) </td>
<td class="formItem">ISOTRETINOIN</td>
<td class="formItem">35Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SOYBEAN OIL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITAN MONOOLEATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYL GALLATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PEG-32 HYDROGENATED PALM GLYCERIDES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (blue) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">23mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">G;343</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10631-134-31</td>
<td class="formItem">3  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10631-134-69</td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021951</td>
<td class="formItem">06/08/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Ranbaxy Laboratories Inc.
							(169932519)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Galephar Pharmaceutical Research Inc. (003551624)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Galephar Pharmaceutical Research Inc.</td>
<td class="formItem"></td>
<td class="formItem">003551624</td>
<td class="formItem">ANALYSIS(10631-115, 10631-116, 10631-117, 10631-133, 10631-134, 10631-118), MANUFACTURE(10631-115, 10631-116, 10631-117, 10631-118, 10631-133, 10631-134), PACK(10631-115, 10631-116, 10631-117, 10631-118, 10631-133, 10631-134)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BASF PharmaChemikalien GmbH &amp; Co. KG</td>
<td class="formItem"></td>
<td class="formItem">328633636</td>
<td class="formItem">API MANUFACTURE(10631-115, 10631-116, 10631-117, 10631-118, 10631-133, 10631-134)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>aaa8a771-1687-448a-83cb-80ad3fde51c7</div>
<div>Set id: 8d54aab5-3349-4a41-8533-0a566fd7bbaa</div>
<div>Version: 4</div>
<div>Effective Time: 20140827</div>
</div>
</div>Â <div class="DistributorName">Ranbaxy Laboratories Inc.</div></p>
</body></html>
